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Abstract 
Introduction: Elderly patients are at increased risk of adverse medication events (ADEs) and 
potentially inappropriate medicines (PIMs).  The STOPP START tool has been validated to assess 
medications of elderly patients for potentially inappropriate prescribing.  There is little data on 
prescribing patterns for elderly Australian hospital inpatients.  This Thesis aims to describe changes 
in prescribing as measured by the STOPP START tool in elderly patients throughout a hospital 
admission including admission and discharge from a specialised geriatric evaluation management 
(GEM) unit.  This Thesis also assessed the effect of inclusion of a pharmacist on a physician-led ward 
round on the quality of prescribing in elderly hospitalised patients.  The number of medications 
prescribed for each patient on admission to hospital, on transfer to the GEM unit and at discharge 
from the GEM unit for both the pre-intervention and post-intervention group were also compared. 
 
Method: This Thesis used an observational retrospective design to study the quality of prescribing in 
two groups of patients, pre- and post-intervention, using the STOPP START tool at three points 
during hospital stay; admission to hospital, transfer to a specialised geriatric unit and discharge from 
hospital.  Data was collected over 4 months pre- and post-introduction of a pharmacist to a physician-
led ward round. Demographic and clinical data, including total number of medications and STOPP 
START criteria met, were collected.  The number of STOPP START criteria at the different time 
points, was compared between the pre- and post-intervention groups to determine whether there was 
a change in potentially inappropriate prescribing after the intervention of a pharmacist participating 
on the ward round.  The mean number of STOPP START criteria (the total number of criteria met 
divided by number of patients) at each time point were compared pre- and post-introduction of a 
pharmacist using a Mann-Whitney U test.  The mean number of criteria for each time point within 
both the pre- and post-intervention groups were compared using a paired Wilcoxon test. 
 
Results: The demographics of the participants in the pre- and post-intervention groups were similar.  
In the ninety-six pre-intervention group patients, 58 (60.4%) were female, the median age was 83 
[IQR 76-87] years and the mean number of co-morbidities was 5.10. The post-intervention group had 
one hundred patients, 55 (55%) were female and the median age was 84 [IQR 78-89].  The post-
intervention group had 21% less STOPP START criteria at discharge, mean 1.18 (SD 1.37) compared 
to the pre-intervention group 1.50 (SD 1.41), p=0.07. The pre-intervention group had no significant 
change in the criteria from admission 1.78 (SD 1.57) to geriatric unit transfer 1.72 (SD 1.54) (p=0.37) 
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however there was a significant 13% decrease from geriatric unit transfer 1.72 (SD 1.54) to discharge 
1.50 (SD 1.41) (p=0.02).  The post-intervention group had a 26% decrease in criteria from hospital 
admission 2.30 (SD 1.91) to geriatric unit transfer 1.59 (SD 1.60) (p<0.01) and again to discharge 
1.18 (SD 1.37) (p<0.01).  
 
The total number of medications prescribed per patient in the pre-and post-intervention groups were 
not significantly different between the groups at admission (median 7 [IQR 5-10] vs 8 [IQR 5-10], 
p=0.4) or discharge (median 8 [IQR 6-11] vs 9 [IQR7-11], p=0.5).  However, in the individual groups, 
the number of medications increased from admission to discharge (pre-intervention group 7 [IQR 5-
10] to 8 [IQR 6-11], p<0.01), (post-intervention group 8 [IQR 5-10] to 9 [IQR 7-11], p<0.01). 
 
 
Conclusion: This Thesis found that prescribing quality changed for elderly patients during admission 
to an Australian hospital.  During the acute hospital stay potentially inappropriate prescribing did not 
change significantly for the pre-intervention group however a decrease in STOPP START criteria 
was seen in the post-intervention group.  This Thesis found that after admission to the GEM unit 
prescribing quality improved, as measured by less STOPP START criteria on discharge in both the 
pre- and post-intervention groups.  We observed that whilst the number of prescribed medicines per 
patient increased, potentially inappropriate prescribing was reduced during the hospital stay.  The 
lesser amount of STOPP START criteria for the post-intervention group on discharge compared to 
the pre-intervention group is evidence that pharmacist participation on physician ward rounds can 
improve prescribing quality and supports pharmacist participation on ward rounds as a valuable 
addition to the pharmaceutical care provided by clinical pharmacists.   
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Chapter 1: Literature Review 
Prescribing for elderly patients can be particularly challenging due to changes in pharmacokinetics, 
pharmacodynamics and multiple co-morbidities.  As such, elderly patients are at increased risk from 
adverse drug effects (ADEs) and potentially inappropriate medicines (PIMs).  Whilst the risks of 
medication misadventure, such as falls, ADEs and hospitalisation are well documented, there has 
been less evidence of effective interventions to improve prescribing and decrease these risks. 
 
There are also gaps in the published literature around current patterns in prescribing for elderly 
patients throughout a hospital admission, including admission to a specialised geriatric unit.  The 
impact of a pharmacist participating in a physician-led ward round in a geriatric unit has also not been 
previously studied. 
 
This Thesis aims to describe changes in prescribing as measured by the STOPP START tool in elderly 
patients throughout a hospital admission including admission and discharge from a specialised 
geriatric evaluation management (GEM) unit.  This Thesis will also assess the effect of inclusion of 
a pharmacist on a physician-led ward round on the quality of prescribing in elderly hospitalised 
patients and the number of medications prescribed for each patient. 
 
1.1 Elderly Population 
The Australian population over 65 years old is increasing in both number and proportion.  Those aged 
over 65 are expected to make up 25% of the Australian population in 20561.  In 2013, they represented 
3.3 million people (14.4% of the population)2.   
 
The total expenditure on health as a percentage of gross domestic product (GDP) in Australia has 
increased from 7.8% in 1999 to 8.7% in 20083.  In the same time period, the per capita expenditure 
on pharmaceuticals and other medical non-durables has increased from $290(US) in 1999 to 
$503(US) in 20083.  These statistics demonstrate a trend of increasing health and pharmaceutical 
spending.  As more medication becomes available and longevity increases, the use of medication by 
the elderly will increase further4.  Data from the USA suggests that while the population over 65 
accounts for 13% of the total population, it also accounts for the largest per capita consumers of 
prescription medications5 6.  Trend analysis into Government expenditure on medications funded by 
the Pharmaceutical Benefits Scheme (PBS) in Australia showed that persons aged 65 years and over 
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contributed to over half of all Government expenditure and nearly two-thirds of all the growth in PBS 
expenditure in the time period analysed (2006-2011)7.  
 
Elderly patients also consume a disproportionate amount of healthcare resources with 35% of hospital 
admissions in 2004-2005 for patients over 658.  Growing population numbers and healthcare spending 
will reach a point of unsustainability.  Judicious use of healthcare resources is important from both a 
fiscal and quality use of medications perspective. 
 
1.2 Potentially Inappropriate Prescribing 
Quality Use of Medicines (QUM) is one of the central objectives of Australia’s National Medicines 
Policy9.  
 
QUM means:  
• Selecting management options wisely;  
• Choosing suitable medicines if a medicine is considered necessary; 
• Using medicines safely and effectively; and 
• Maintaining a viable pharmaceutical industry9.  
The definition of QUM applies equally to decisions about medicine use by individuals and decisions 
that affect the health of the population9.  The term ‘medicine’ includes prescription, non-prescription 
and complementary medicines9.  The optimisation of prescribing for elderly patients by reducing 
potentially inappropriate prescribing follows the principles of QUM. 
 
Despite the best intentions of treating medical practitioners, there can be cases of suboptimal 
prescribing for individual elderly patients.  The term potentially inappropriate prescribing is 
frequently used in the literature to encompass the use of medicines that introduce a significant risk of 
an adverse drug-related event where there is evidence for an alternative, equally or more effective, or 
associated with a lower risk, to treat the same condition4 10.  Potentially inappropriate prescribing may 
lead to a significant risk of an ADE10.  Potentially inappropriate prescribing also includes the use of 
medications at a higher frequency and for longer than clinically indicated, the use of medicines that 
have recognised, clinically significant drug-drug interactions or drug-disease interactions, and also 
the underuse of beneficial medicines that are clinically indicated but not prescribed despite evidence 
based medicine4. 
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1.3 Medication Use in Elderly Patients 
Regulatory bodies usually consider older people to be those aged 65 years and older11.  Despite the 
wide intra-group variability, this age delineation is well-recognized and this group of older or elderly 
patients has the potential to have different physiological properties to the general adult population.  
These differences can raise challenges in prescribing.  Pharmacological treatment is an important 
component of medical care for the elderly and whilst potentially beneficial it also has the potential to 
decrease morbidity and mortality and increase quality of life12.  Problems associated with 
pharmacological treatment are frequent among elderly hospitalised patients and for a significant 
number of patients it can lead to a medication-related hospital admission12.   
 
There are age related changes to pharmacokinetics and pharmacodynamics of medicines that lead to 
a reduction in physiological reserves, as outlined in Table 113.  Additionally differences in receptor 
numbers and binding affinities, changes in target organ responses and impaired compensatory 
reflexes also result in less predictable outcomes13.  Cytochrome P450 oxidation declines with ageing 
and drug-drug interactions involving these enzymes are important to recognise14 15. 
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Table 1: Pharmacokinetic and pharmacodynamics changes in the elderly13 
Action With ageing Significance 
Absorption/ 
first pass 
Unchanged absorption 
Reduced first pass metabolism 
(reduced liver mass, reduced blood 
delivery to liver) 
Same amount of medication absorbed, 
but increased bioavailability of some 
drugs (e.g. metoprolol, nortriptyline) 
Volume of 
distribution 
Increased body fat in proportion to 
lean muscle 
 
Decreased body water 
Prolonged half-life of fat soluble 
drugs (e.g. diazepam) 
Increased serum concentrations of 
water soluble drugs (e.g. digoxin, 
paracetamol) 
Protein binding Lower serum albumin 
concentration in frail or unwell 
elderly 
Increased free concentrations of 
highly protein bound drugs (e.g. 
warfarin, phenytoin) 
Metabolism Reduced oxidative metabolism 
(liver) 
Unchanged conjugative 
metabolism (liver) 
Prolonged half-life, higher steady 
state concentrations of some drugs 
(e.g. diazepam, metoprolol, 
phenytoin) 
Excretion Reduced with decreased 
glomerular filtration rate (GFR) 
and tubular excretion 
Prolonged half-life, higher steady 
state concentrations of some drugs or 
metabolites (e.g. digoxin, cephalexin, 
morphine) 
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1.3.1 Adverse Drug Events 
The prevalence of adverse drug events (ADEs) is increased in older patients and reactions are 
generally more severe11.  A large prospective UK study identified 6.5% of hospital admissions were 
due to ADEs and 72% were avoidable16.  Patients with ADEs were also significantly older (median 
age 76) compared to those without  (median age 66)16.  A German population-based study reported 
that drug-related hospitalisation was five times higher in the elderly17.  In an Australian study using 
data from 1988-2001, drug-related problems were responsible for up to 30% of all hospital admissions 
for patients over 75 years and it was estimated that three quarters of these admissions were 
avoidable18.  At least 40 000 older Australians are hospitalised each year as a result of medication 
related problems, representing 20-30% of unplanned hospital admissions in this age group19 20.  
 
ADEs can be difficult to detect in elderly patients as they often exhibit non-specific symptoms such 
as lethargy, confusion, light-headedness, falls, constipation and depression4.  The ADE rate in the 
elderly is at least three times that of the general population4.  Additionally up to 20% of re-admissions 
in geriatric patients were found to be medication related21.  It was estimated that 75% of these 
admissions could have been prevented if medications had been used more appropriately21.     
 
1.3.2 Polypharmacy 
Polypharmacy is usually defined as taking five or more medications, including prescribed, over the 
counter and complementary medications22.  There is an extensive use of medications in older people 
given that increasing age is a major risk factor for disease, disability and co-morbidity11 23.  The 
prevalence of chronic diseases, for which one or more medications may be indicated, increases with 
age22.  Concurrent use of several medications may be justifiable in the treatment of multiple chronic 
diseases.  Polypharmacy is known to dramatically increase the risk of ADRs, drug-drug and drug-
disease interactions4.  The risk of a potential ADRs increases with the number of medications 
prescribed, rising from an incidence of 13% if two drugs are prescribed, to 38% with four drugs 
prescribed and to 82% if seven or more drugs are prescribed4 24. Elderly patients use an average of 
two to five medications on a regular basis and polypharmacy is present in 20-40% of elderly 
patients25.  Polypharmacy may also occur when additional medications are prescribed to treat the 
adverse effects of another medication, known as the prescribing cascade26. 
 
Polypharmacy and inappropriate medicine use correlates with increasing age, co-morbidity, disability 
and number of medications27.  It is also associated with the likelihood of nursing home placement, 
impaired mobility, morbidity, hospitalisation and death27.  The increased risk of falls is associated 
with polypharmacy, partly due to the chronic diseases for which multiple medications are 
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prescribed22.  The increased use of specific classes of medication, especially centrally-acting and 
cardiovascular medications, is also likely to be a risk factor in increasing the falls risk28.   
 
Polypharmacy has also been associated with under-prescribing29.  The probability of under-
prescription increases with an increase in the number of medications used, common examples were 
the omission of laxatives for patients prescribed opioids or beta blockers following myocardial 
infarction.  As the number of medications prescribed increases, it is possible prescribers are reluctant 
to start new medications, including those which could be of benefit for the patient.  Polypharmacy 
alone is not a clinically useful independent marker of the quality use of medicines22.  The medication 
type and dose, rather than the number of medications, can determine more meaningful clinical 
outcomes30.  An increased number of medications may be appropriate if prescribing quality is 
maintained and all medications prescribed are appropriate for the individual patient.  There is also 
evidence that prescribing quality can influence quality of life31.  There is validity supported by the 
literature in the basic principle of prescribing quality, the more appropriate the medication, the better 
quality of life for the patient29 31.   
 
 
1.4 Tools for Identifying Potentially Inappropriate Prescribing  
Assessment of prescribing quality or potentially inappropriate prescribing can be assessed using 
implicit (judgement-based) or explicit (criteria-based) methods32.  Each medication is assessed 
individually and a potentially inappropriate medication (PIM) can be flagged.  PIMs have limited 
effectiveness in older adults and have been associated with serious ADEs such as delirium, 
gastrointestinal bleeding, falls and fractures33 34. 
 
Implicit criteria, such as the Medication Appropriateness Index (MAI) are used to assess each 
medication prescribed for a patient considering its indication, effectiveness, dosage, correct direction, 
cost and other clinical information required to determine appropriateness35.  The reviewer is required 
to have a comprehensive knowledge of medications to confidently perform this assessment32 and 
there is a degree of subjectivity.  
 
An alternative method of identifying PIM in the elderly is to use validated screening tools that 
incorporate explicit prescribing indicators4.  Explicit PIM criteria have been developed by a 
consensus panel using the modified Delphi method32.  The research group constructs criteria or 
statements about the appropriateness of specific medication use on the basis of a review of the 
literature32.  Selected experts are asked to rate their agreement with statements about these 
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medications using a Likert scale32.  Statements with high degree of agreement are circulated for a 
second or third rating32.  Consensus is reached for the PIMs that generate a high level of agreement 
amongst the experts32.  An example of a criteria from the STOPP tool (explicit tool) is “digoxin at a 
long-term dose >125 microgram per day with impaired renal function”36. 
 
There have been several explicit criteria developed, in different settings and countries, each with its 
own advantages. 
 
1.4.1 Beers Criteria 
Beers criteria were first published in 1991, are an explicit list of PIMs for nursing home residents37.  
A modified Delphi technique was used to derive consensus opinion on prescribing indicators from a 
panel of 13 experts in geriatric medicine, long-term care, geriatric and psychogeriatric pharmacology 
and pharmacoepidemiology37.  The expert panel produced a list of 30 medications to be avoided in 
nursing home residents37.  There were subsequent revisions in 1997 and 2003 to include all settings 
of geriatric care37-39.   
 
The latest update published in 2012 used a comprehensive systematic review and grading of the 
evidence on drug-related problems and adverse drug events in older adults40.  There are 53 
medications or medication classes divided into three categories: PIMs and classes to avoid in older 
adults, those to avoid in older adults with certain diseases and syndromes and medications to use with 
caution in older adults40.  It is proposed that application of the criteria will allow for closer monitoring 
of drug use, application of real-time e-prescribing and interventions to decrease ADEs in older adults 
and to obtain improved  patient outcomes40.  Observational studies have shown a strong link between 
the medications listed in Beers criteria and poor patient outcomes including ADEs, hospitalisation 
and mortality 27 33 34 41-46.   
 
Criticism of the Beers Criteria has been that as the list was developed in the USA, it reflects 
medications that are used there and may be not used in other countries, particularly Europe4 and 
Australia47.  Beers criteria have significant limitations when applied in Australia as it contains many 
medications which have never been available in Australia, some that have been withdrawn from use 
in Australia and medications which are used infrequently47.  These limitations have led many 
researchers to attempt to adapt the Beers criteria to reflect their own healthcare settings and this limits 
the transferability of results. 
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Additionally, it does not include all causes of potentially inappropriate prescribing, for example, drug-
drug interactions are not included4.  Controversy also exists over some of the medications considered 
inappropriate by Beers, eg. amitriptyline (a tricyclic antidepressant) which is useful in a broad range 
of pain syndromes at varying doses4.  The criteria also only consider the prescribing of PIMs and not 
the under-prescribing of clinically indicated drugs and other drug-management issues4.  The criteria 
are not organised according to physiological systems48 and the 2012 revision has resulted in a tool 
that is quite cumbersome to use as there are several sections to consider. 
 
1.4.2 Improved Prescribing in the Elderly Tool (IPET) 
The IPET was first published in 200049 as an attempt to update McLeod’s criteria which were 
developed based on a Canadian medication formulary50.  IPET was developed as a quick tool 
comprising of 14 questions representing potentially inappropriate prescribing, for example “beta-
blocker in patient with chronic obstructive airways disease or asthma”49.  It has several deficiencies; 
it is not based on physiological systems and the criteria are not comprehensive.  There are also 
outdated questions, such as the avoidance of beta-blockers in heart failure, which are now accepted 
as clinically appropriate. 
 
1.4.3 Australian Prescribing Indicators 
An Australian group published a suggested a list of prescribing indicators in 2008 based on frequent 
medical conditions which elderly patients consult their general practitioner for and cross-referenced 
these conditions with common prescribed medications by volume47.  This resulted in a list of 48 
prescribing indicators, which included 45 explicit criteria47.  There is also a supplementary table of 
contraindications and precautions to consider before commencing medications that may be suggested 
by the tool47.  This tool has been used by pharmacists to successfully identify drug related problems 
in elderly patients51.  The resulting tool and supplement are quite cumbersome to use, and the tool 
has a mix of medications that should be used and medications that should not be used interspersed 
through the table.  Whilst it was produced using local, relevant information this also limits the tools 
ability to be compared to international data. 
 
1.4.4 Other Criteria  
There have been several other criteria developed internationally that have been less popular in the 
literature.  Developed by a team of geriatricians in Canada, the Rancourt criteria has four categories: 
medications, duration, dosage and drug-drug interactions52.  The Laroche Criteria include a set of 36 
criteria published in France for use in patients aged 75 years or older53.  The first Asian PIM criteria 
(Winit-Watajana), developed in Thailand, includes 77 statements divided into high-risk medications 
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with potential ADRs, high risk medications with drug-disease interactions and high risk medications 
with drug-drug interactions54.  They also regrouped the medications/medication classes into drugs 
which should be avoided, drugs that are rarely appropriate, drugs with some indications for older 
patients and unclassified drugs54.  The usefulness of this tool is limited by 70% of drugs being in the 
unclassified group32.  Thirty-six medications or medication classes were considered potentially 
inappropriate based on Norwegian expert consensus the NORGEP criteria for patients over 70 
years55.  There were no statements for drug-drug interactions or alternatives32. 
 
1.4.5 STOPP START 
STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions) and START 
(Screening Tool to Alert to the Right Treatment) are two validated tools comprising of 65 and 22 
explicit criteria respectively36.  The validity was first established through a Delphi consensus process 
involving 18 experts in geriatric pharmacotherapy from Ireland and the United Kingdom, including 
geriatric physicians, senior hospital pharmacists with an interest in geriatric pharmacotherapy, senior 
academic primary care physicians and a specialist geriatric psychiatrist36.  The criteria are organised 
by body system for ease of use and are designed to be used together to ensure a comprehensive 
assessment of older persons’ medications. 
 
The STOPP START tools have been used to describe rates of potentially inappropriate prescribing in 
a range of international settings across Europe, Asia and northern America56. 
 
The STOPP tool has been shown to detect more PIMs than Beers criteria (2003 revision) and almost 
twice as many PIMs with a causal or contributory relationship to hospital admission57.  STOPP 
START criteria medications have been significantly associated with ADEs, unlike Beers criteria 
200358.  The STOPP START criteria has also been shown to predict hospitalisations due to potentially 
inappropriate prescribing59.  The STOPP START criteria have been found to be associated with a 
significant number of acute hospital admissions in frail older persons59. Fall-induced osteoporotic 
fracture was the most frequent cause of hospital admission related to inappropriate prescribing59.  
STOPP START criteria used as an intervention to improve prescribing during hospitalisation for an 
acute illness was effective in improving medication appropriateness with an effect lasting 6 months 
post discharge60.  In a further study applying STOPP START criteria to individual patients within 72 
hours of admission to hospital significantly reduced ADRs and reduced average length of stay 
(LOS)61.   
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The STOPP START tool version 2 was published in 2014, updating and expanding the original list 
of criteria61.  The new version has been validated only by Delphi consensus panel61, and there is yet 
to be published data on its practical and clinical application, however the list of criteria appear 
promising. 
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1.5 Comparison of Criteria 
Some of the newer criteria are limited by the lack of published studies in English32.  It has been 
proposed that there are several criteria to consider when deciding on which tool is more appropriate62.  
These are shown below in table 2, adapted from Chang32 and the seven criteria described by 
O’Mahoney and Gallagher are listed as the criteria for assessment in the column on the left of table 
2.   
 
Table 2: Evaluation of the seven criteria against the principles of optimal explicit criteria for 
potentially inappropriate medications (PIMs) 
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Organisation based on physiological 
systems and rapid applicability in 
daily practice 
- - +/- +/- + - - 
Inclusion of common prescribing 
errors 
+/- +/- +/- +/- +/- +/- +/- 
Generalisability to a global 
community of physicians & 
pharmacists 
+/- +/- +/- +/- +/- +/- +/- 
Ease of interface with computer 
records of patients and drug lists 
- - +/- + +/- +/- + 
Ability to reduce the prevalence of 
PIMs 
+ + + NS + NS NS 
Ability to reduce the incidence and 
negative impact of ADRs 
NS NS NS NS NS NS NS 
Ability to predict ADEs and/or 
hospitalisation 
+ - NS NS + NS NS 
NS = no studies; + indicates fully met; +/- indicates partially met; - indicates not met. 
 
The STOPP/START tool has been selected for use in this Thesis as it was the tool which came closest 
to meeting the ideal tool32.  For this Thesis the choice of criteria had to be supported by literature 
demonstrating effectiveness in measuring prescribing, be practical to apply and useful in the 
Australian hospital environment.  The combination of STOPP with START, gives a set of explicit 
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criteria which are easy to apply and has been validated to assess for prescribing quality in the elderly57.  
The medication classes and treatment recommendations are congruent with the Australian setting63 
and the tool has been validated for minimal variability between users64.  This led to STOPP START 
being the tool chosen to measure the prescribing quality of Australian elderly hospital patients in this 
study.  STOPP START was chosen as a practical method of measuring the effect of an intervention 
to improve prescribing quality (Appendix D). 
 
STOPP START was designed for prescribers or clinicians to guide or assess their potential 
prescribing against a set of explicit criteria and to guide better choices.  In the setting of this Thesis, 
the STOPP START tool will be used as a de facto measure of prescribing quality.  Using the tool as 
a quality measure is an extension of the original design as an assessment tool, however it enables the 
comparison of two models of care.   
 
1.6 Interventions to Improve Prescribing 
There have been numerous interventions studied to assess for impact on prescribing quality or 
polypharmacy.  These interventions have been in several different settings and are often multi-faceted 
which makes comparison of effect difficult.  Whilst the settings may be varied, numerous studies and 
reviews are described below to provide background.  Also, the small study numbers and multiple 
approaches make conclusive, outcome based results difficult to obtain65 66, so considering different 
study designs and settings could identify directions to guide future studies. 
 
A Cochrane review conducted in 2014 concluded that it was unclear whether interventions to reduce 
inappropriate polypharmacy had a clinically significant improvement however these interventions, 
which often included pharmaceutical care, appear beneficial in terms of reducing inappropriate 
prescribing66.  Pharmaceutical care was complex to assess, as it was often multi-faceted as an 
intervention66.  Pharmaceutical care often reflected a systematic approach that ensures the patient 
receives the correct medication, at an appropriate dose for an appropriate indication and often 
involves a collaborative approach between the pharmacist, physician and patient66.  In 2016 a separate 
Cochrane review found that several interventions improved medication appropriateness, the 
identification and resolution of medication-related problems, a slower decline in health-related 
quality of life and fewer days in hospital in older patients from care homes65. 
 
Individual studies into interventions to improve prescribing include educational interventions, 
medication reviews, geriatricians‘ services, multidisciplinary teams, computerised support systems, 
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regulatory policies and multi-faceted approaches10.  These interventions are displayed below in Table 
3, adapted from Kaur10. The studies listed as successful interventions, are those which demonstrated 
a significant improvement in prescribing, based on each study’s definition 10.  There were 
encouraging results for multidisciplinary teams, interventions from a pharmacist, computerised 
support for the physician or pharmacist and some regulatory policies.  
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Table 3: Types of interventions used to reduce inappropriate prescribing, adapted from Kaur10 
Intervention Type Unsuccessful Successful 
Educational Interventions Audit results and guidelines mailed to GPs67 
 
Small group workshop, use of decision tree or 
both68 
 
Feedback about prescribing and evidence 
mailed to GPs69 
 
Three-step approach of quarterly reports, 
biannual onsite visits and annual meetings70 
 
Regulatory Policies 
 
Inclusion of list of inappropriate medications 
in drug use protocol71 
 
PBS restriction of inappropriate drugs for 
elderly patients72 
 
 Mandated pharmacy services in nursing 
homes73 
 
Multi-Faceted Approach 
 
Combining age-specific computerised alerts 
with academic detailing74 
 
 
Computerised Support System 
 
 Medication alert to pharmacist when 
dispensing75 
 
 Computerised alerts triggering telephone call 
to physician by pharmacist76 
 
 Computerised decision support system for 
physician77 
 
Pharmacist Interventions 
 
 Medication review78-80 
 
 Pharmacist coordinated transition from 
hospital to long-term care facilities81 
 Pharmacist consultation to patients and 
physicians82 83 
Multidisciplinary Teamwork 
 
 Pharmaceutical care provided by a 
pharmacist with direct contact with unit84 
 Case conferences85 
 Presentation of feedback of internal audit at 
multidisciplinary staff meetings86 
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Educational interventions were varied and had different results.  An interactive workshop combined 
with a treatment algorithm had more impact on prescribing non-steroidal anti-inflammatory drugs 
(NSAIDS) to elderly patients than presenting a patient with a treatment algorithm68.  However an 
intervention that focused on discussing the results of an audit of proton pump inhibitors (PPIs) 
prescribing with general practitioners (GPs) had no impact on the rates of PPI prescribing67.  Passive 
approaches such as mail outs or listing inappropriate medications in a protocol manual did not 
produce a change69.  A three-step approach involving quarterly reports, biannual onsite visits and 
annual network meetings showed that always inappropriate and sometimes inappropriate medication 
use decreased70.   
 
Computerised support systems have had success as an intervention to improve prescribing66.  A 
computerised pharmacy alert system to the pharmacist then collaboration between healthcare 
professionals decreased PIM use in elderly patients75.  Another study showed that computer-based 
access to a complete medication profile combined with alerts to potential prescribing problems to the 
pharmacist followed by a call to the physician reduced the number of some PIMs76.  When the 
physician was provided with a computerised decision support system the number of new PIM 
prescriptions was lowered77.  Computerised support systems integrated into e-Prescribing could 
support the prescriber to consider assessing or changing “high-risk” medications and serve as a good 
reminder of contra-indications such as age or disease state.   
 
Pharmacist intervention has been successful in improving prescribing10, however the definition of 
pharmacist intervention is varied.  Medication review and written recommendation to the physician 
decreased the MAI number87, inappropriate prescribing80 and PIM83.  Medication review at discharge 
from hospital and follow-up with the patient by a pharmacist was also successful at improving 
prescribing79 81.  An acute care for elders (ACE) pharmacist who consulted on all patients decreased 
the prevalence of Beers criteria on discharge compared to admission of a hospital stay for elderly 
patients82.   Several studies have used an intervention model in acute care, or hospital based patients 
that involves a pharmacist performing a medication history on admission, medication reviews and 
individual patient counselling during admission and communication with the patient and primary care 
provider on discharge88.  A study conducted in Belgium found that pharmacist intervention increased 
the medication appropriateness, as measured by MAI and under-prescribing criteria and showed a 
trend toward decreased mortality and emergency department visits84.  A Swedish study found that 
pharmacist intervention in patients over the age of 80 admitted to hospital had morbidity benefits; 
decreased emergency department visits, hospital visits and drug-related readmissions89.  In a second 
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Swedish study, multidisciplinary input on medications which included a pharmacist showed a 
decrease in drug-related hospital visits and MAI score12. 
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1.7 Pharmacist Interventions on Ward Rounds 
 
There is evidence that the addition of a pharmacist to the healthcare team can help to improve the 
quality of medicine use and reduce patient risk in a range of hospital settings. For example, a senior 
pharmacist decreased the incidence of adverse drug events (ADEs) when they participated as a full 
member of the patient care team, making rounds with the physicians in an ICU setting92.  The rate of 
preventable ADEs due to prescribing errors decreased by 66% and the pharmacist made 366 
prescribing interventions, of which 362, or 99%, were adopted92. 
 
A pharmacist added to a rounding team in a general medical unit has been shown to reduce 
preventable ADEs by 78%93.  Another study identified 150 interventions by a pharmacist on a ward 
round, of which 147 were adopted94. A pharmacist on a post-take ward round has been shown to have 
a range of quantitative benefits leading to optimised treatment for individual patients95.   They 
improved the accuracy of drug history documentation, reduced prescribing costs and decreased the 
potential risk to patients95.  Recommendations regarding a specific drug, modifying the drug dose and 
reviewing the need for drug treatment were the most common interventions out of a total of 109 
interventions for 53 patients95.  Most interventions were rated as minor or moderate and there were 4 
interventions rated as major relating to potential problems that could result in permanent harm to the 
patient95.   
 
It was felt these results were promising evidence that the addition of a pharmacist to the physician 
led ward round would lead to an improvement in the quality of prescribing.  The high adoption rate 
of recommendations or interventions is evidence that this would be an optimal setting to ensure 
effective communication of treatment recommendations.  The effect of a pharmacist on ward rounds 
in a specialised geriatric unit has not yet been studied.  
1.8 Chapter Conclusion 
Elderly patients are particularly at risk of a medication related adverse event.  Changes in metabolism, 
increased co-morbidities and increasing frailty make prescribing particularly challenging.  
Prescribing quality can be measured using a specifically designed tool, such as STOPP START.  It is 
proposed that STOPP START is appropriate for assessing prescribing patterns and measuring the 
effect of an intervention, specifically the addition of a pharmacist to a physician-led ward round. 
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Chapter 2 – Aim and Methods 
2.1 Aim 
The aim of this study is to assess the effect of pharmacist ward round participation on prescribing 
quality as assessed by the STOPP-START tool in hospitalised elderly patients.   
 
2.2 Specific Aims 
1. Describe the current pattern of prescribing for geriatric patients at several points of hospital 
admission at the Royal Brisbane and Womens Hospital (RBWH) using the STOPP START 
tool. 
2. Describe the number of regular medications prescribed for geriatric patients at several points 
of hospital stay at the RBWH. 
3. Evaluate the impact of pharmacist participation on physician-led ward rounds on prescribing 
quality in an interventional phase of the study. 
4. Explore the impact a pharmacist has on clinical decision making around prescribing  
 
2.3 Hypotheses 
Prescribing quality will be improved after the addition of a pharmacist to physician-led ward rounds 
(post-intervention) in the GEM unit.  Specifically: 
1. Patients in the post-intervention group will have fewer STOPP START criteria met on 
discharge from the GEM unit compared to the pre-intervention group. 
2. Patients in the post-intervention group will have fewer STOPP START criteria met on 
discharge from the GEM unit compared to admission to hospital and admission to the 
GEM unit. 
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2.4 Method 
2.4.1 Study Design 
This study was a retrospective analysis of two data periods a pre- and a post-intervention phase.  The 
pre-intervention phase was from April – August 2012.  The post-intervention phase included data 
from September 2012 to February 2013. 
 
2.4.2 Setting 
The study was conducted in the Geriatric Evaluation and Management (GEM) Unit in the Department 
of Internal Medicine at the Royal Brisbane and Women’s Hospital (RBWH).  
The RBWH is a 929 bed tertiary referral teaching hospital located at Herston, Brisbane.  The RBWH 
is in the Metro North Health District of Queensland Health.  It is a key provider of health care services 
providing high quality care over a large range of specialities including medicine, surgery, 
orthopaedics, obstetrics, gynaecology, neonatal intensive care and trauma services.  It is the largest 
tertiary referral hospital in Queensland and provides more than one tenth of all patient services in 
Queensland.  It also serves patients in northern New South Wales and the Pacific Rim. 
 
The GEM Unit is a 28 bed ward located on the Herston campus of the RBWH.  The GEM unit was 
established in April 2012. This geriatric service specializes in optimizing independence and 
functional outcomes for the frail older person.  The GEM model of care aims to return elderly patients 
to their achievable or maximal level of independence.  
 
GEM patients are usually over the age of 65 and have specific treatment or assessment goals that can 
benefit from time in the specialised unit such as a need to increase mobility to return home or 
comprehensive psychological assessment to best determine treatment options in cognitive decline. 
The GEM team aims to provide a holistic, multi-disciplinary team approach.  The medical team is led 
by a geriatrician, specialised nursing staff, senior pharmacist and specialist allied health team 
including physiotherapists, occupational therapists, speech pathologists, dieticians, clinical 
psychologists, neuropsychologists, social workers and allied health assistants.  There are a complex 
series of assessments and patient reviews to ensure each patient receives tailored treatment aimed at 
meeting their needs.  The team meet regularly to review each patient’s progress and report back to 
the patient and/or carer.  The patient journey through the RBWH and GEM unit is presented in figure 
1.   
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In the pre-intervention phase (i.e. before clinical pharmacist presence on ward round) the clinical 
pharmacist service was restricted to providing a medication review on admission to the unit, daily 
chart reviews to advise on dose, duration and route of medications, discharge planning and 
participation in the multi-disciplinary case meetings, but not ward rounds.  This was representative 
of how most of the clinical pharmacist services were delivered at this hospital for general medical 
and surgical wards at this time.  In September 2012, when the post-intervention data collection 
commenced, the pharmacist had commenced participating on the physician-led ward rounds up to 
twice each week.  At this time the pharmacist stopped attending the multi-disciplinary case meetings 
and received advice on the outcomes of these meetings from the discharge facilitator.   
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Figure 1 Patient journey through RBWH GEM unit 
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2.4.3 Assessment of Intervention Choice  
When assessing which intervention to assess for potential to improve prescribing in elderly patients, 
it is imperative to consider the standard care already provided and what measures are being used to 
evaluate the quality of prescribing.  The term “pharmaceutical care” or “pharmacist review” can have 
multiple meanings and often involves multi-faceted interventions66.  The standard clinical pharmacist 
care in our setting (outlined in chapter 3) already includes several of the potential interventions 
described in the above section.   
 
Pharmacist review by an ACE Pharmacist using the Beers criteria as an intervention and prompt can 
lead to a reduction in the number of Beers criteria met82. An enhanced pharmacist model has been 
shown to improve the appropriateness of prescribing for Swedish hospital patients as demonstrated 
by decreased mean STOPP and START criteria and decreased MAI score90.  The enhanced service 
included medication reconciliation and review, drug-related problems were discussed by the 
pharmacist with the physician in charge and follow-up was provided to the primary care physician 
and patient90.  There is evidence from a Belgium study that admission to a geriatric unit with a 
pharmacist can improve medication appropriateness 84.  When the specialised clinical pharmacist is 
involved in the collaborative review of the patient with direct contact with the geriatric team the 
appropriate use of medications improved during the hospital stay and at discharge compared to 
patients who received a more limited pharmacist review84.  These studies describe a model of care 
that is already utilised within our Australian metropolitan hospital setting. 
 
There is evidence that physicians do not review the medication chart for every patient on each ward 
round91 and may not view the pharmacists written recommendations.  This would be likely for any 
written communication, as evidenced by a low uptake rate in the study which used faxed 
recommendations80.  There is however promising evidence that when a pharmacist discusses 
medication issues verbally with the physician in charge, that patient scores can decrease for STOPP 
START, and prescribing appropriateness could improve90.  
 
With the low potential for written, didactic recommendations to improve appropriateness of 
prescribing, and improved outcomes when oral communication is direct with the physician, this study 
aims to place the intervention closer to the point of prescribing decision making, on the physician-led 
ward round. 
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2.4.4 Ethics 
The pre-intervention phase was granted ethics exemption by the RBWH Human Research Ethics 
Committee (HREC/12/QRBW/115) see Appendix A.   The post-intervention phase was approved by 
the RBWH Human Research Ethics Committee (HREC/15/QRBW/212) see Appendix B.   
 
2.4.5 Patients:  
 
Inclusion Criteria:  
- All patients aged 65 years and older on admission to the GEM Unit 
 
Exclusion Criteria: 
- Patients assessed as suitable for end of life care by the palliative care team 
- Patients transferred from the GEM unit to another specialty acute or rehabilitation team other 
than the GEM unit 
 
2.4.6 Design 
Pre-Intervention: 
Data was collected from all eligible patients admitted over a period of four months from April to 
August 2012 with an initial target of 100 patients.  Patients were identified prospectively and data 
collected throughout their admission.  The data was collected and evaluated by the candidate.  
Standard clinical pharmacy services were provided by a clinical pharmacist who was experienced in 
the care of hospital inpatients, including the elderly, performing a daily clinical review including 
admission review of medication, advice provided on dose, duration and route, discharge planning and 
participation in the multi-disciplinary case meetings.  Most communication regarding medication was 
with a junior medical officer or communicated in a written manner on a medication action plan 
(MAP).  
 
Intervention: 
After the pre-intervention period a change was made to the model of care in the GEM unit.  A clinical 
pharmacist was included on physician-led ward rounds, providing advice on optimising patient’s 
individual medication regimens and documenting suggestions on the MAP.  This advice was 
communicated directly with either the physician or registrar.  The major point of difference to the 
pre-intervention group is the communication was directed at a different level of medical prescriber.  
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This is a model of care that has been successfully used in other clinical areas including intensive care 
and general medical wards to improve prescribing outcomes96-99.  There were different clinical 
pharmacists involved in the GEM unit during the data collection periods, with two different primary 
pharmacists involved.  There was a pharmacist staff change between the pre and post-intervention 
groups.  The primary pharmacists involved had similar levels of hospital clinical pharmacist 
experience with a specific interest in geriatrics.  Further analysis of the differences between 
pharmacists and prescribers was not conducted as part of this Thesis.   
 
In the absence of local data to enable a formal sample size calculation, an a priori target patient 
inclusion target of 100 eligible patients was used as had been chosen in similar studies using an 
intervention model78 100 101. 
 
 
2.4.7 Data Collection   
Data collection was consistent for both phases of the study.  Patient demographic information, 
presenting complaint, presenting diagnosis, co-morbidities, medications and pathology were recorded 
on a data collection tool (Appendix C).  A complete list of the patient’s medication was also collected 
from the patient’s current National Inpatient Medication Chart (NIMC), MAP, discharge medication 
record (DMR) and/or the discharge prescription.  PIMs and potential prescribing omission criteria 
were identified using the data collection tool, consisting of the STOPP START tool as a proxy 
measure of prescribing quality (see Appendix D).  Medical notes were consulted to ensure that all 
factors regarding appropriateness were considered.  If medication was ceased or commenced, details 
regarding the change will be recorded on the data collection tool. 
 
Identified patients were followed longitudinally across the admission with data collection occurring: 
- Stage 1 – on admission to hospital, after review by a clinical pharmacist and the admitting 
consultant.  Any medication discrepancies between the NIMC and MAP at this point were 
investigated to determine if changes were intentional, and this information was noted on 
the data collection tool. 
- Stage 2 - on admission to the GEM unit 
- Stage 3 – on discharge from the GEM unit 
 
2.4.8 Outcome Measures 
The primary outcome measure was the mean number of STOPP START criteria identified at each 
timepoint (mean number of criteria = total number of criteria identified divided by total number of 
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patients).  Secondary outcome measures were the total number of medications and individual STOPP 
START criteria identified. 
All outcome measures were compared within each group (pre-intervention or post-intervention) and 
between the two groups. 
 
 
2.4.9 Data Analysis 
The data were analysed using Microsoft Excel (Microsoft Office 2011; Redmond, WA) and 
GraphPad Prism 6 (GraphPad Software 2015; La Jolla, CA).   
 
Data are presented as median [interquartile range] or mean (standard deviation) as appropriate. To 
assess the primary outcome the Mann-Whitney U test was used to analyse the differences in the 
number of criteria identified at each time-point between the pre- and post-intervention groups.   
 
To analyse the differences in the number of STOPP START criteria within each group between 
time-points to assess where any change to prescribing quality may have occurred a paired Wilcoxon 
test was used.  In this analysis admission was compared to transfer to the geriatric unit and transfer 
to geriatric unit was compared to discharge for both groups.   
 
To compare the number of medicines prescribed at each of the three time-points within each group 
a paired Students t-test was used; with admission to hospital compared to transfer to the geriatric 
unit and transfer to geriatric unit compared to discharge from hospital.  To compare the proportion 
of patients that met each individual STOPP START criteria at the three time-points within each 
group and the proportion of patients that met at least one STOPP or START criteria at each time-
point the Chi-Square test was used. 
 
An unpaired Students t-test was used to compare continuous data between the pre- and post-
intervention groups. A Chi-square test was used to compare categorical data between the pre- and 
post-intervention groups. A p-value <0.05 was considered statistically significant for all analyses. 
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Chapter 3: Submitted manuscript: An evaluation of prescribing using 
STOPP START criteria throughout a hospital admission - does a geriatric 
management unit improve prescribing in elderly patients?  
 
The manuscript titled “An evaluation of prescribing using STOPP START criteria throughout a 
hospital admission – does a geriatric management unit improve prescribing in elderly patients.” Has 
beem submitted to the journal, Drugs – Real World Outcomes, in December 2016. 
 
 
The manuscript is included as submitted except tables have been inserted into the text.  The 
numbering of pages, figures and tables and references have been adjusted for overall continuity.  
 
KEYWORDS: STOPP START, geriatric, pharmacy, inappropriate prescribing 
 
3.1 Chapter Introduction 
This chapter aims to describe the current patterns of prescribing for Australian hospital inpatients 
using the STOPP START tool.  This is a significant addition to the published literature.  Additionally, 
it provides a comparison of the STOPP START tool at three time-points to allow comparison of the 
prescribing quality across a hospital admission, including a stay in a specialised geriatric unit.  The 
chapter begins to describe the first two of the Thesis’ specific aims; describe the current pattern of 
prescribing for geriatric patients at several points of hospital admission at the Royal Brisbane and 
Womens Hospital (RBWH) using the STOPP START tool and describe the number of regular 
medications prescribed for geriatric patients at several points of hospital stay at the RBWH.  The 
group described in this chapter form the pre-intervention group and provide the baseline data set for 
this Thesis.   
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3.2 Introduction 
The elderly population is commonly defined as those over 65 years. In Australia, this population is 
an extremely diverse group 11 that is increasing in both number and proportion. In 2013, they 
represented 3.3 million people (14.4% of the population)2.  Elderly patients consume a 
disproportionate amount of healthcare resources accounting for 38% of hospital admissions in 2010-
11 and 48% of inpatient days8.   
 
The incidence and severity of adverse drug-related events (ADEs) is increased in the elderly 
patients11.  At least 40,000 elderly Australians are hospitalised each year as a result of medication-
related problems, representing 20-30% of unplanned hospital admissions in this age group, many of 
which are avoidable10 32 64. Given these healthcare challenges, specialist geriatric units that maximize 
independence and functional outcomes for the elderly are increasing in size and number throughout 
Australia. 
 
The term inappropriate prescribing is frequently used to encompass a use of a medicine that increases 
the risk of an ADE where there is evidence for an equally or more effective alternative, or associated 
with a lower risk, to treat the same condition4 10.   It can also include the use of a medication for an 
unapproved indication, for no indication, for an inappropriate duration or treatment that is 
unnecessarily expensive. Inappropriate prescribing also includes the failure to prescribe appropriate 
therapy. 
 
Potentially inappropriate prescribing can be assessed using implicit (judgement-based) or explicit 
(criteria-based) methods32. There are a number of validated tools that can be used to assess potentially 
inappropriate prescribing in the elderly.  STOPP (Screening Tool of Older Persons’ Potentially 
inappropriate Prescriptions) and START (Screening Tool to Alert to the Right Treatment) are two 
validated tools comprising of 65 and 22 explicit criteria respectively36.   
The STOPP tool may be favoured over Beers criteria (2003 revision) as the STOPP tool detects more 
potentially inappropriate prescribing that has a causal or contributory temporal relationship to hospital 
admission59.  STOPP START has also been shown to predict hospitalisations due to potentially 
inappropriate prescribing59.  The STOPP START criteria have been found to be associated with a 
significant number of acute hospital admissions in frail older persons59.   
 
There is evidence that admission to a geriatric unit with input from a pharmacist can improve 
medication appropriateness84.  When a pharmacist performs a medication history close to admission 
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including reconciliation and review, discussion of medication problems with the physician and 
follow-up with the patient and primary care physician the appropriateness of prescribing has been 
shown to improve, demonstrated by decreased mean STOPP and START criteria and decreased MAI 
score90.  There has been a lack of published literature describing the patterns of prescribing quality 
for patients throughout their hospital admission. 
 
The primary aim of this single-centre study is to describe current prescribing patterns as measured by 
the STOPP START tool in elderly patients throughout a hospital admission including admission to a 
specialised geriatric unit.  
 
 
3.3 Methods 
3.3.1 Setting 
The setting for this study was a specialised 28 bed geriatric unit within a 950-bed public Australian 
tertiary hospital.  In this unit, patients are referred from inpatient medical and surgical teams and 
>95% are over 65 years.  This unit accepts referrals for patients with functional goals that require 
expert geriatric staff, including physiotherapists, occupational therapists, psychologists, dieticians, 
social workers, speech pathologists, pharmacists and a specialist geriatrician. The aim of the unit is 
to rehabilitate patients to enable them to become sufficiently functional to return home.  A clinical 
pharmacist service was also present providing admission review of medication, advice on dose, 
duration and route of medications, discharge planning and participation in the multi-disciplinary case 
meetings.  Prior to admission the general pharmacist service included medication reconciliation 
performed shortly after admission to hospital, regular (every 1-3 days) clinical pharmacist review and 
input in the multidisciplinary team. 
 
3.3.2 Patients  
Data were collected from all eligible patients admitted over a period of four months from April to 
August 2012 with an initial target of 100 patients.  Patients were prospectively assessed for eligibility 
according to the following criteria: 
 
Inclusion Criteria:  
- All patients aged 65 years and older on admission to the specialised geriatric unit 
 
Exclusion Criteria: 
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- Patients assessed as suitable for end of life care by the palliative care team 
- Patients transferred from the specialised geriatric unit to another specialty acute or rehabilitation 
team  
 
3.3.3 Data Collection and Design 
Identified patients were followed longitudinally throughout the entire hospital admission with data 
collection occurring at three stages: 
1. On admission to hospital 
2. On transfer to the specialised geriatric unit 
3. On discharge from the specialised geriatric unit 
 
Patient demographic information, presenting complaint, presenting diagnosis, co-morbidities and 
pathology was collected from the patient’s medical notes and hospital pathology provider.  A 
complete list of the patient’s medication was also collected from the inpatient medication chart and 
other medication records, discharge medication record and/or the discharge prescription.  Potentially 
inappropriate medication and potential prescribing omission alerts were identified using the STOPP 
START tool.  
 
This study used an observational, retrospective design.  The same group of patients were compared 
at three timepoints to assess for any changes in prescribing quality.  The primary outcome measure 
was the mean number of STOPP START criteria identified at each timepoint (mean number of criteria 
= total number of criteria identified divided by total number of patients).  Secondary outcome 
measures were the total number of medications and individual STOPP START criteria identified. 
 
3.3.4 Analyses 
In the absence of local data to enable a formal sample size calculation, an a priori target patient 
inclusion target of 100 eligible patients was used as had been chosen in similar studies using an 
intervention model90.  Data are presented as mean (standard deviation) or median [interquartile range] 
as appropriate.  
 
To assess the primary outcome; the mean number of STOPP START criteria identified at each 
timepoint (admission to hospital, transfer to the specialised geriatric unit, discharge from the 
specialised geriatric unit), a Wilcoxon matched-pairs signed rank test was used. The mean number of 
criteria from admission was compared to geriatric unit transfer and the mean number of criteria from 
geriatric unit transfer was compared to hospital discharge.  A Wilcoxon matched-pairs signed rank 
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test was also used to compare the mean number of medicines prescribed at the three different 
timepoints in the same manner.  
 
The proportion of patients with at least one STOPP or START criteria at each timepoint was 
compared using a Chi-square test. The presence of individual STOPP START criteria at the three 
different timepoints was also compared using a Chi-square test.  Each Chi-square test compared the 
data from two individual timepoints to assess for any change.   
 
 p<0.05 was considered statistically significant.   
 
3.3.5 Ethics 
This study was granted ethics exemption by the Royal Brisbane and Womens Hospital Human 
Research Ethics Committee (HREC/12/QRBW/115).    
 
3.4 Results 
Ninety-six patients were eligible for inclusion.  The demographic and clinical characteristics of the 
patients are described in Table 4. Most of the patients lived at home prior to hospital admission. Less 
than half of those patients returned home after hospital discharge (Table 4).  Patients had been referred 
to the specialised geriatric unit from a variety of surgical, medical and oncology speciality teams. The 
leading causes of hospital admission for these patients were falls in 34 (35.4%) patients, infections 
(n=9, 9.4%), difficulty coping at home (n=9, 9.4%) and the requirement for specialised care during 
cancer treatment (n=9, 9.4%).  Included patients had a mean number of co-morbidities of 5.10 
conditions per patients.  The most prevalent co-morbidities are listed (Table 4) and had a broad range 
of affected organ systems including cardiovascular, falls, endocrine and gastrointestinal. 
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Table 4: Demographic and clinical data for patients evaluated 
 Male Female 
Sex 38 (39.6%) 58 (60.4%) 
Age 83 [IQR 76-87] 
Accommodation Type Pre-Hospital After Discharge 
Home 82 (85.4%) 35 (36.5%) 
Independent Living; e.g. 
retirement home 
5 (5.2%) 3 (3.1%) 
Aged Care Facility  9 (9.4%) 41 (42.7%) 
Transition Care Program 0 17 (17.6%) 
Mean number of co-
morbidities per patient 
5.10 
Prevalent co-morbidities, 
number of patients (%) 
Hypertension: 56 (58.3%)  
Increased falls risk: 33 (34.4%) 
Osteoporosis: 31 (32.3%) 
Atrial fibrillation: 30 (31.3%) 
Interstitial heart disease: 30 (31.3%) 
Increased cholesterol: 27 (28.1%) 
Gastro-oesophageal reflux disease: 25 (26.0%) 
Osteoarthritis: 25 (26.0%) 
Diabetes: 24 (25%) 
 
 
 
Patients had a mean hospital length of stay of 39.5 (20.2) days of which 22.2 (16.7) days were in the 
specialised geriatric unit.  The mean number of medications prescribed per patient showed a 
significant increase from admission 7.3 (4.3) to discharge 8.8 (4.6), p<0.01.  
 
At hospital admission 55 patients (57.3%) met one or more STOPP criteria for a potentially 
inappropriate medication prescribed and 48 patients (50%) had at least one START criteria for a 
medication that may have been inappropriately omitted.  On hospital discharge 55 patients (57.3%) 
met at least one STOPP criteria for a potentially inappropriate medication prescribed and 41 patients 
(42.7%) had at least one START criteria for a medication that may have been inappropriately omitted.  
These proportions were not significantly different (p=1 for STOPP and p=0.3 for START). 
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The mean number of STOPP START criteria (total number of criteria divided by number of patients) 
decreased from hospital admission 1.78 (1.57) to geriatric unit admission 1.72 (1.54) and again to 
discharge 1.50 (1.41).  The decrease in mean number of criteria from geriatric unit transfer to hospital 
discharge was significant, p=0.02.  The decrease in mean number of criteria from hospital admission 
to discharge was also significant, p=0.02.  
 
The five most common STOPP alerts are described in Table 5.  The most common START criteria 
are described in Table 6.  The changes between time-points for each individual criteria were not 
significantly different.  
 
 
Table 5: The five most prevalent STOPP criteria (for the pre-intervention group) 
Criteria Description Number of Patients that met criteria (% of all patients) 
 Admission Geriatric unit 
transfer 
Discharge 
PPI for peptic ulcer disease at full 
therapeutic dosage for > 8 weeks 
29 (30.2%) 30 (31.2%) 26 (27.1%) 
Loop diuretic for dependent ankle 
odema only (ie. no clinical signs of 
heart failure) 
11 (11.6%) 9 (9.4%) 8 (8.3%) 
 
Drugs that adversely affect those 
prone to falls (>1 fall in the past 3 
months) – benzodiazepines 
12 (12.5%)  9 (9.4%) 7 (7.3%)   
Long-term long-acting 
benzodiazepines 
9 (9.4%) 5 (5.2%) 4 (4.2%) 
Drugs that adversely affect those 
prone to falls – neuroleptic drugs 
4 (4.2%) 5 (5.2%) 4 (4.2%) 
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Table 6: The five most prevalent START criteria alerts (for the pre-intervention group) 
 Number of Patients that met criteria  
(% of all patients) 
Criteria description Admission Geriatric 
unit transfer 
Discharge 
Calcium and vitamin D supplement in 
patients with known osteoporosis 
14  
(14.6%) 
16  
(16.7%) 
13  
(13.5%) 
Antiplatelet therapy in diabetes with 
one or more cardiovascular risk factors 
11  
(11.5%) 
10  
(10.4%) 
7  
(7.3%) 
Warfarin in the presence of chronic 
atrial fibrillation OR aspirin if warfarin 
is contra-indicated 
6  
(6.3%) 
5  
(5.2%) 
5  
(5.2%) 
Statin therapy with a documented 
history of coronary, cerebral or 
peripheral vascular disease, where the 
patient’s functional status remains 
independent for activities of daily living 
5  
(5.2%) 
6  
(6.3%) 
4  
(4.2%) 
ACE Inhibitor or angiotensin receptor 
blocker in diabetes with neuropathy or 
microalbuminuria 
6  
(6.3%) 
5  
(5.2%) 
5  
(5.2%) 
 
3.5 Discussion 
We observed a significant decrease in mean number of STOPP START criteria met by patients after 
a stay in a specialised geriatric unit.  There was a 13% reduction, or 0.22 criteria per patient in the 
number of STOPP START criteria identified after the stay in the specialised geriatric unit.  There 
was also an overall decrease, or 16% in STOPP START criteria met from hospital admission to 
discharge from the geriatric unit.  The overall decrease is largely influenced by the significant change 
during the geriatric unit admission, however there was also a small trend of decrease during the acute 
hospital admission.   
 
Interestingly, we observed a significant increase in the number of medications prescribed on 
admission to hospital (7.3 per patient) to that prescribed on discharge, (8.8 per patient). Indeed, the 
risk of medication misadventure increases for each additional prescribed medication above 5 
medications102, suggesting that this increase has clinically significant consequences, although 
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polypharmacy alone should not be considered a clinically useful marker of the quality use of 
medicines22.  To this end, the medication type and dose, rather than the number of medications, can 
determine more meaningful clinical outcomes30.  The decrease in potentially inappropriate 
prescribing, as measured using STOPP START criteria, during the hospital admission would suggest 
that the slight increase in number of medications could indicate more appropriate prescribing. In this 
present study, this result suggests that the increases in prescribed medications were appropriate.  
 
The results from our study are similar with previous international data.  On admission to hospital 57% 
of patients met at least one STOPP criteria and 50% met at least one START criteria.  A similar study 
of Australian hospital inpatients identified 60% of patients had at least one STOPP criteria upon 
admission to hospital63. Irish studies have identified rates of STOPP criteria between 34-50% in 
hospital patients and 60% in nursing home patients62.  Studies across six European countries 
(Switzerland, Spain, Ireland, Czech Republic, Italy and Belgium) found an overall rate of 51.3% for 
STOPP criteria and 59.4% for START criteria for hospital patients56. 
 
The leading STOPP criteria, PPI therapy for peptic ulcer disease at full therapeutic dosage for > 8 
weeks (27.1% of patients on discharge), is consistent with other study data that showed that PPI use 
within the wider patient group is very common103.  Chronic PPI use is associated with increased rates 
of community acquired pneumonia, increased Clostridium difficile-associated diarrhoea, 
malabsorption resulting in vitamin B12 deficiency and possibly higher fracture rates103.  Recent 
evidence suggests that PPI use is associated with an increased risk of developing dementia and 
avoidance of PPI medication could contribute to the prevention of dementia104.   These risks are 
particularly relevant to older patients and are all important reasons why all prescribers should 
carefully review the use and duration of PPI therapy.  The small decrease in inappropriate PPI use 
from geriatric unit transfer to hospital discharge indicates appropriate deprescribing in this patient 
group. Deprescribing, or the trial withdrawal of specific classes of medications that may be 
inappropriate for the individual patient can lead to a reduction in ADEs105.  There can also be 
decreased medication costs to the patient and healthcare system, improved medication adherence and 
improved patient satisfaction from taking fewer medications105.  There is evidence that multi-
disciplinary review by a pharmacist and physician can reduce the rate of potentially inappropriate 
prescribing in an outpatient clinic setting by targeting deprescribing106.   
 
The number of patients prescribed benzodiazepines decreased from 12.5% patients on admission to 
7.3% on discharge.  This reduction is considered appropriate as use of benzodiazepines has been 
associated with an increased risk of falls28.   
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The START alerts were also high in these patients and may represent missed opportunities to increase 
the appropriate use of medications.  There were a high proportion of patients, 13.5% on discharge, 
that were not prescribed calcium and vitamin D despite a diagnosis of osteoporosis.  Calcium and 
vitamin D co-supplementation for the treatment of osteoporosis are well accepted in literature and 
guidelines107 108.  This study period was before concerns were raised in the literature regarding the 
safety of calcium supplementation109.  A relatively high number of patients (5.2% at discharge) had 
a diagnosis of atrial fibrillation (AF) and were not receiving aspirin or warfarin for secondary stroke 
prevention, despite evidence of effect108 and no documented contra-indication.  Statin use was also 
lower than expected, with 4.2% patients at discharge with a history of coronary, cerebral or peripheral 
vascular and independent in daily living activities that were not prescribed a statin. 
 
The results described above, summarized as an increase in the number of medications prescribed per 
patient and a modest decrease in the mean number of START STOPP criteria was less significant 
than hypothesized.  There could be numerous reasons why these results were seen.  During a hospital 
admission, particularly for this patient group, there are numerous treatment goals. Many of these are 
focused on ensuring the patient can meet the functional goals required to return home.  A recent 
Australian study of specific geriatrician review of medications for new nursing home patients did not 
show significant change to high risk medications110.  This was thought to be suggestive of the 
medications being appropriate on balance for the specific patient or, because of other factors, such as 
an unwillingness to change medications110.  Pharmacotherapeutics may not be considered a high 
priority for patients in the geriatric unit and may be overlooked in place of other therapy goals or 
social concerns.   
 
These patients had quite a lengthy admission to hospital, with the mean total admission to hospital 
approaching 40 days, 22 of which were spent within the specialised geriatric unit.  A long period of 
hospital admission especially within a specialised geriatric unit does provide a sufficient opportunity 
for medical and pharmacy staff to completely review and tailor individual medication regimens.  
There is some evidence that admission to a geriatric unit with a pharmacist can improve medication 
appropriateness84.  When the specialised clinical pharmacist is involved in the collaborative review 
of the patient with direct contact with the geriatric team the appropriate use of medications improved 
during the hospital stay and at discharge compared to patients who received a more limited pharmacist 
review84.  A specialised geriatric unit may allow for the controlled trial of new medications or trial of 
medication withdrawal under close observation with easy access to pathology and other services. 
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These results have some limitations as they represent the findings from a single centre study.  The 
services provided in a large, metropolitan hospital may not be available at all sites so may not be able 
to be duplicated at other sites.  Additionally, the STOPP START tools were initially described to 
guide prescribing and may lack sensitivity to accurately described prescribing changes. 
   
3.6 Conclusion 
This study has described the current pattern of prescribing for elderly hospital inpatients in a tertiary 
referral centre with a specialised geriatric unit.  We observed that the overall quality of prescribing 
did improve after admission to a geriatric unit however the number of medications prescribed did 
increase during the hospital admission.   Further work is required to investigate the effects of 
interventions designed to further improve prescribing quality for this important group of older 
patients. 
3.7 Chapter Summary 
 
This chapter has described the current pattern of prescribing quality for elderly hospitalised patients 
that have a stay in a specialised geriatric unit, summarised as an overall improvement in prescribing 
quality despite an increase in the overall number of prescribed medications.  This group of patients 
form the pre-intervention group for the Thesis and will form the baseline data for comparison with 
the post-intervention group in the next chapter, Chapter 4. 
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Chapter 4: Accepted Manuscript: The effect of pharmacists on ward rounds 
measured by the STOPP START tool in a specialised geriatric unit  
 
The manuscript titled “The effect of pharmacists on ward rounds measured by the STOPP START 
tool in a specialised geriatric unit” has been accepted for publication by the Journal of Clinical 
Pharmacy and Therapeutics, 13th November 2016, DOI: 10.1111/jcpt.12489. 
 
The manuscript is included as submitted except tables have been inserted into the text.  The 
numbering of pages, figures and tables and references have been adjusted for overall continuity.  
 
KEYWORDS:  
Inappropriate prescribing, STOPP START, pharmacist ward rounds, prescribing quality, elderly 
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4.1 Chapter Introduction 
This chapter continues to describe patterns in prescribing quality for elderly hospitalised patients.  
The results from the pre-intervention group, as described in chapter 3, are compared to new results 
from the post-intervention group using a before and after study design in two groups of elderly 
patients.  The aim of this Thesis is to assess the effect of pharmacist ward round participation on 
prescribing quality as assessed by the STOPP-START tool in hospitalised elderly patients.  
Additionally, this chapter also addresses the four specific aims:   
 
1. Describe the current pattern of prescribing for geriatric patients at several points of hospital 
admission at the RBWH using the STOPP START tool. 
2. Describe the number of regular medications prescribed for geriatric patients at several points 
of hospital stay at the RBWH. 
3. Evaluate the impact of pharmacist participation on physician-led ward rounds on prescribing 
quality in an interventional phase of the study. 
4. Explore the impact a pharmacist has on clinical decision making around prescribing. 
 
These aims are assessed using the outcome measures first discussed in Section 2.4.8 Outcome 
Measures.  The primary outcome measure was the mean number of STOPP START criteria identified 
at each timepoint (mean number of criteria = total number of criteria identified divided by total 
number of patients).  Secondary outcome measures were the total number of medications and 
individual STOPP START criteria identified. 
 
All outcome measures were compared within each group (pre-intervention or post-intervention) and 
between the two groups. 
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4.2 Background 
The incidence and severity of adverse drug-related events (ADEs) is increased in elderly patients11, 
commonly defined as individuals 65 years of age or older. Medication-related problems are a 
frequent cause of unplanned hospital admissions in this age group, many of which are avoidable10 32 
64.  The term inappropriate prescribing is frequently used to encompass the use of a medication that 
increases the risk of ADEs where there is evidence for an equally or more effective alternative, or 
associated with a lower risk, to treat the same condition4 10.   It can also include the use of a 
medication for an unapproved indication, for no indication, for an inappropriate duration or 
treatment that is unnecessarily expensive4or the failure to prescribe appropriate therapy36. 
 
The original STOPP (Screening Tool of Older Persons’ Potentially inappropriate Prescriptions) and 
START (Screening Tool to Alert to the Right Treatment) tools comprise of 87 validated, explicit 
criteria36.  A previous systematic review has described that the combined STOPP START tool has 
been used as a measure of prescribing quality111.  The use of the criteria has been shown to decrease 
falls, delirium episodes, hospital length of stay, care visits (primary and emergency) and medication 
costs111.  STOPP START criteria have also been shown to predict hospitalisations due to potentially 
inappropriate prescribing59.  The STOPP START tool is therefore used as an accepted measure for 
potentially inappropriate prescribing, or prescribing quality.  Previous work has used the STOPP 
START criteria to measure the effect of an enhanced pharmacist service on prescribing in elderly 
hospital patients90. 
 
The addition of a pharmacist to the physician-led ward round has provided evidence of improved 
prescribing quality in other clinical settings.  A pharmacist added to the physician-led rounding 
team has been shown to reduce preventable ADEs by 78% in a general medical unit 99 and 66% in 
an intensive care unit92.  The presence of a pharmacist on a physician-led general medical ward 
round shortly after admission has also been shown to improve the accuracy of drug history 
documentation, reduce prescribing costs and decrease the potential risk to patients96.  
Recommendations regarding drug choice, dose and need for drug treatment were the most common 
interventions leading to optimisation of treatment for individual patients96.  There is evidence that 
suggestions made by a pharmacist on a ward round are adopted, in two studies the rate was 98% 98 
and 99%92.  No published data currently exists for whether addition of a specialised clinical 
pharmacist to a physician-led geriatric ward round can improve the appropriate use of medications 
during the hospital stay and at discharge. 
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This study aimed to assess the effect of inclusion of a pharmacist on a physician-led ward round on 
potentially inappropriate prescribing in hospitalised elderly patients. 
 
4.3 Methods 
4.3.1 Design 
This was an observational cohort study to assess changes in prescribing quality using the STOPP 
START tool (2008 version) that occurred pre- and post- addition of a clinical pharmacist to a 
physician-led ward round in a specialised geriatric unit. The first cohort, or pre-intervention group, 
consisted of patients admitted to the specialised geriatric unit between April to August 2012. The 
second cohort, or post-intervention group, consisted of patients admitted from September 2012 to 
February 2013 at which stage a pharmacist had been added to physician ward rounds. The addition 
of the clinical pharmacist to the ward round was considered the only change to the model of care at 
this time, however there were changes to the pharmacist and medical staff during this time. 
 
4.3.2 Setting 
This study was conducted in a 28-bed specialised geriatric unit within a 950-bed tertiary referral 
hospital in Australia.  The specialised geriatric unit patients are referred from inpatient medical and 
surgical teams. The role of the unit is to optimise treatments that can enable the patient to become 
sufficiently functional to return home or to community based care.  
 
Multi-disciplinary clinical care (includes physiotherapists, occupational therapists, psychologists, 
dieticians, social workers, speech pathologists) led by a specialist geriatrician is provided in the unit 
as standard practice. Pre-intervention, the clinical pharmacist service included providing a 
medication review on admission to the unit, daily chart reviews to advise on dose, duration and 
route of medications, discharge planning and participation in the multi-disciplinary case meetings, 
but not ward rounds.  General pharmacist service (prior to admission to the specialised geriatric 
unit) included medication reconciliation performed shortly after admission to hospital, regular 
(every 1-3 days) clinical pharmacist review and input in the multidisciplinary team.  In September 
2012, when the post-intervention data collection commenced, the pharmacist began participating on 
the twice-weekly physician-led ward rounds.  Pharmacist tasks on the physician-led ward round 
included participating in discussion about medication appropriateness, dose and duration of 
treatment.  At this time, the pharmacist stopped attending the multi-disciplinary case meetings and 
received advice on the outcomes of these meetings from the discharge facilitator.  The mean length 
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of stay of over 20 days for each group enabled the pharmacist to regularly review each patient as 
part of the twice weekly ward rounds(post-intervention) or ward meetings(pre-intervention). 
 
4.3.3 Patients  
All patients admitted to the specialised geriatric unit were retrospectively assessed for eligibility 
according to the following criteria: 
 
Inclusion Criteria:  
- Patients aged 65 years and older on admission to the specialised geriatric unit 
 
Exclusion Criteria: 
- Patients transferred from the geriatric unit to: 
- An acute medical, surgical or rehabilitation team or unit 
- A palliative care team or unit 
 
4.3.4 Data Collection 
In the pre- and post-interventions groups, patients were identified and followed longitudinally 
across the entire hospital admission with data collection at three stages: 
1. On admission to the hospital 
2. On transfer to the specialised geriatric unit 
3. On discharge from the specialised geriatric unit 
 
Patient demographic and clinical information was collected from the patient’s medical notes and 
hospital pathology provider, including presenting complaint, co-morbidities and pathology.  The 
patient’s complete medication list was also collected from the inpatient medication chart and other 
medication records.  The STOPP START tool was used to identify potentially inappropriate 
medication and potential prescribing omission criteria.  Medical notes were reviewed to ensure that 
all factors regarding appropriateness were considered.   
 
The primary outcome was the differences between the pre- and post-intervention groups for 
changes to the number of STOPP START criteria at the times of; hospital admission, transfer to the 
geriatric unit and hospital discharge.  The secondary outcomes were the longitudinal differences in 
prescribing within the pre- and post-intervention groups. We also evaluated the total number of 
medications prescribed and the most common individual STOPP START criteria identified in both 
groups. 
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4.3.5 Analyses 
Data are presented as mean (standard deviation) or median [interquartile range] as appropriate. A 
Mann-Whitney U test was used to analyse the primary outcome, the differences in the number of 
criteria identified at each time-point between the pre and post-intervention groups.   
 
A paired Wilcoxon test was used to analyse the differences in the number of STOPP START 
criteria within each group between time-points to assess where any change to prescribing quality 
may have occurred; admission was compared to transfer to the geriatric unit and transfer to geriatric 
unit was compared to discharge for both groups.   
 
A paired Students t-test was used to compare the number of medicines prescribed at the three 
different time-points within each group; with admission to hospital compared to transfer to the 
geriatric unit and transfer to geriatric unit compared to discharge from hospital.  The Chi-Square 
test was used to compare the proportion of patients that met each individual STOPP START criteria 
at the three time-points within each group and the proportion of patients that met at least one 
STOPP or START criteria at each time-point. 
 
An unpaired Students t-test was used to compare continuous data between the pre- and post-
intervention groups. A Chi-square test was used to compare categorical data between the pre- and 
post-intervention groups. A p-value <0.05 was considered statistically significant for all analyses.   
 
4.3.6 Ethics 
This study was granted low risk ethics approval by the RBWH Human Research Ethics Committee 
(HREC/15/QRBW/212).    
 
4.4 Results and Discussion 
Ninety-six patients were included in the pre-intervention group and 100 in the post-intervention 
group, a flowchart describes the total number of patients and exclusions in figure 2. As described in 
Table 7, there were no significant differences between the two groups in their demographic and 
clinical characteristics. 
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Pre-Intervention Group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Post-Intervention Group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Flowchart of patients admitted during the pre- and post intervention study periods 
  
Total number of patients in study 
period = 109 patients 
Excluded due to age < 65 = 7 
patients 
Excluded due to transfer to 
palliative care unit or acute 
treatment unit = 6 patients 
Included in study group = 96 
patients 
Total number of patients in study 
period = 112 patients 
Excluded due to age < 65 = 3 
patients 
Excluded due to transfer to 
palliative care unit or active 
treatment unit = 9 patients 
Included in study group = 100 
patients 
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Table 7: Demographic characteristics of pre- and post intervention groups 
 Pre-intervention group Post-intervention group p 
Number of patients 96 100  
Sex - % male 39.6% 45% 0.39 
Age 83 [IQR 76.25-87] 84 [IQR 78-88.75] 0.19 
Mean total length of 
stay 
40 (20) 42 (34) 0.52 
Mean length of stay 
(days) in specialised 
geriatric unit 
22 (17) 25 (21) 0.29 
Median number of 
medications - 
admission 
7 (IQR 5-10] 8 [IQR 5-10] 0.41 
Median number of 
medications – transfer 
to geriatric unit 
9 [IQR 7-13] 10 [IQR 7-12] 0.26 
Median number of 
medications - 
discharge 
8 [IQR 7-11] 9 [IQR 7-10] 0.47 
Proportion of patients 
living at home pre-
hospital (own home, 
home with family or 
independent living 
unit) 
91% 92% 0.80 
Leading causes of 
hospital admission 
Falls (35%) 
Infection (9%) 
Difficulty coping at home 
(9%) 
Falls (43%) 
Infection (17%) 
Neurological cause (17%) 
 
 
 
 
The results of the mean number of criteria met by the two groups, pre- and post-intervention, at the 
three time-points, admission to hospital, transfer to the geriatric unit and discharge from hospital, 
are described in Table 8.   
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Table 8: Summary of changes to mean number of STOPP START criteria at each time point 
 Mean number of STOPP START criteria (SD) for each group (pre- and post-
intervention) at each time-point 
 Admission p value of 
difference 
between 
admission 
and geriatric 
unit transfer 
Geriatric 
unit 
transfer 
p value of 
difference 
between 
geriatric 
unit 
transfer 
and 
discharge 
Discharge Decrease 
from 
geriatric 
unit 
transfer 
to 
discharge 
Pre-
Intervention 
1.78 (1.57) 0.37* 1.72 (1.54) 0.02* 1.50 
(1.41) 
13% 
Post-
Intervention 
2.30 (1.91) <0.01* 1.59 (1.60) <0.01* 1.18 
(1.37) 
26% 
p value of 
difference 
between 
groups (pre- 
and post 
intervention 
groups) 
0.09^  0.36^  0.07^  
*paired Wilcoxon test 
^Mann Whitney U-test 
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The pre-intervention group did not have a significant change in the mean number of STOPP 
START criteria from hospital admission to geriatric unit transfer however there was a significant 
13% decrease from geriatric unit transfer to discharge.  In the post-intervention group, the mean 
number of STOPP START criteria significantly decreased from hospital admission to geriatric unit 
transfer and again to discharge.  The decrease from geriatric unit transfer to discharge represented a 
26% reduction in the mean number of STOPP START criteria.   
 
The proportion of patients who met at least one STOPP or START criteria at each time-point are 
described in Table 9.  There was no significant difference found between each group at each of the 
three time-points or between each time-point within the pre- and post-intervention group.  There 
was an overall decreasing trend in the post-intervention group, with less patients meeting at least 
one STOPP or START criteria at geriatric unit transfer compared to admission, and less again on 
discharge, however this change was not found to be significant.  The high proportion of patients that 
met at least one criteria at discharge in the post-intervention group (42% STOPP and 35% START) 
could have contributed to the lack of significance for the primary aim, even though these 
proportions are numerically less than the pre-intervention group (54% STOPP and 42% START).   
 
Table 9: Summary of changes to proportion patients that met at least one STOPP and START 
criteria at each time point for the pre- and post-intervention groups 
 Admission Geriatric unit transfer Discharge 
Pre-Intervention 
STOPP Criteria 
57% 58% 54% 
Pre-Intervention 
START Criteria 
50% 49% 42% 
Post-Intervention 
STOPP Criteria 
64% 53% 42% 
Post-Intervention 
START Criteria 
58% 44% 35% 
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The most prevalent STOPP and START criteria for both groups are described in Table 10 and Table 
11 respectively.  For the pre-intervention group, there were no significant differences between the 
proportions of patients meeting each of these criteria at each time-point. For the post-intervention 
group, there were some significant differences in changes to the proportions of patients meeting 
individual criteria between time-points for selected STOPP and START criteria.  
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Table 10: Comparison of prevalent STOPP criteria for each group 
 Number of Patients that met 
criteria (% of all patients)  
Pre-Intervention Group 
Number of Patients that met 
criteria (n=100 patients)  
Post-Intervention Group 
Criteria Description 
A
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PPI for peptic ulcer disease at 
full therapeutic dosage for > 8 
weeks 
29 
(30.2%) 
30 
(31.2%) 
26 
(27.1%) 
23 
(23%) 
21 
(21%) 
19 
(19%) 
Loop diuretic for dependent 
ankle oedema only (no 
diagnosis of heart failure, 
pulmonary oedema or 
hypertension) 
11 
(11.6%) 
9  
(9.4%) 
8  
(8.3%) 
 
10 
(10%) 
6   
(6%) 
4  
(4%) 
Drugs that adversely affect 
those prone to falls (>1 fall in 
the past 3 months) – 
benzodiazepines 
12 
(12.5%)  
9  
(9.4%) 
7  
(7.3%)   
10** 
(10%) 
3**(3%
) 
1  
(1%) 
Calcium channel blockers 
with constipation 
3  
(3.1%) 
3  
(3.1%) 
4  
(4.2%) 
3^^   
(3%) 
11^^ 
(11%) 
10 
(10%) 
Drugs that adversely affect 
fallers - long term opiates  
3   
(3.1%) 
4  
(4.2%) 
3  
(3.1%) 
9     
(9%) 
7   
(7%) 
7  
(7%) 
TCAs with an opiate or 
calcium channel blocker 
3  
(3.1%) 
3  
(3.1%) 
3  
(3.1%) 
2^^^ 
(2%) 
8^^^ 
(8%) 
10 
(10%) 
**p=0.04 (between admission and transfer to the specialised geriatric unit within the post-
intervention group) 
^^p=0.03 (between admission and transfer to the specialised geriatric unit within the post-
intervention group) 
^^^p=0.05(between admission and transfer to the specialised geriatric unit within the post-
intervention group) 
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Table 11: Comparison of prevalent START criteria for each group 
 Number of Patients that met 
criteria (% of all patients)  
Pre-Intervention Group 
Number of Patients that met 
criteria (n=100 patients)  
Post-Intervention Group 
Criteria Description 
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Calcium and vitamin D 
supplement in patients with 
known osteoporosis 
14  
(14.6%) 
16  
(16.7%) 
13  
(13.5%) 
30 
(30%) 
28** 
(28%) 
11** 
(11%) 
Antiplatelet therapy in 
diabetes with one or more 
cardiovascular risk factors 
11  
(11.5%) 
10  
(10.4%) 
7  
(7.3%) 
5     
(5%) 
4   
(4%) 
4   
(4%) 
Warfarin OR aspirin in the 
presence of chronic atrial 
fibrillation# 
6  
(6.3%) 
5  
(5.2%) 
5  
(5.2%) 
3     
(3%) 
1   
(1%) 
0  
(0%) 
Statin therapy with a history 
of coronary, cerebral or 
peripheral vascular disease 
(functionally independent 
patient)  
5  
(5.2%) 
6  
(6.3%) 
4  
(4.2%) 
6     
(6%) 
5   
(5%) 
5   
(5%) 
Aspirin or clopidogrel with a 
history of atherosclerotic 
coronary, cerebral or 
peripheral vascular disease in 
patients with sinus rhythm 
9  
(9.4%) 
4  
(4.2%) 
3  
(3.1%) 
10 
(10%) 
8   
(8%) 
8  
(8%) 
**p=0.002(between transfer to the specialised geriatric unit and discharge within the post-
intervention group) 
# novel oral anticoagulants and low molecular weight heparin was also accepted in this study as an 
alternative to warfarin for this patient group  
 
 
For the secondary outcomes, the total number of medications prescribed per patient in the pre-
intervention and intervention groups were not significantly different between the groups at 
admission (median 7 [5-10] vs 8 [5-10], p=0.4) or discharge (median 8 [6-11] vs 9 [7-11], p=0.5).  
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However, in the individual groups, the number of medications increased from admission to 
discharge (pre-intervention group 7 [5-10] to 8 [6-11], p<0.01), (post-intervention group 8 [5-10] to 
9 [7-11], p<0.01). 
 
On admission to hospital the post-intervention group had numerically more STOPP START criteria 
identified on admission to hospital, 2.30 (1.91) compared to the pre-intervention group 1.78 (1.57), 
p=0.09.  The mean number of STOPP START criteria upon transfer to the specialised geriatric unit 
was not found to be significantly different between the pre-intervention group, 1.72 (1.54) and the 
post-intervention group, 1.59 (1.60), p=0.36.  For the primary outcome, at hospital discharge, the 
post-intervention group had numerically less STOPP START criteria 1.18 (1.37) compared to the 
pre-intervention group 1.50 (1.41), p=0.07.  The post-intervention group had a 21% fewer mean 
number of criteria, or 0.32 less criteria per patient at discharge when compared to the pre-
intervention group.  The post-intervention group had a larger decrease (26%) in the mean number of 
criteria from geriatric unit transfer to discharge compared to the pre-intervention group (13%).   
 
In this study, we found that inclusion of a pharmacist on a physician-led ward round in a specialised 
geriatric unit was associated with a numerical improvement in prescribing quality compared to the 
existing clinical pharmacist service.  Both groups had a significant decrease in the number of 
STOPP START criteria met at discharge when compared to geriatric unit transfer, however this 
decrease was larger in the post-intervention group.  The lower number of criteria in the post-
intervention group is encouraging for the involvement of the pharmacist on the physician-led ward 
round in a specialised geriatric unit and may have clinical significance, but requires testing in a 
larger cohort of patients. 
 
STOPP START is a validated tool for assessing the appropriateness of prescribing. STOPP criteria 
have been associated with avoidable ADEs that cause or contribute to hospitalisation in elderly 
patients58.  Previous studies have shown that a pharmacist on physician-led ward rounds can reduce 
ADEs 92 99, improve accuracy of medication histories, reduce prescribing costs and decrease 
potential risk to patients96. This study has demonstrated that the mean number of STOPP START 
criteria met by each patient did decrease after a stay in a specialised geriatric unit, and that this 
decrease is larger when the pharmacist is included on the physician-led ward round.  The inclusion 
of the pharmacist on the physician-led ward round placed the pharmacist where prescribing 
decisions are made with access to the medication chart.  The standard methods of the pharmacist 
reviewing the medication chart, identifying a potential issue and then discussing with the medical 
team had numerous barriers – the medication charts were not at the team meetings and outside the 
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meeting it was often the more junior medical officers available on the ward and they may feel 
unable to make changes to a patient’s medication without consultant input.  The use of STOPP 
START criteria as a measure of prescribing quality can enable practitioners to assess the value in 
changes to the model of care.  As such, the decrease in STOPP START criteria was an objective 
measure of a change to the pharmacist model of care.  The results of this study add to the literature 
that pharmacist participation in physician-led ward rounds can improve prescribing quality as 
measured using STOPP START.  
 
We found that both the pre- and post-intervention groups showed a significant decrease in STOPP 
START criteria from the time of intra-hospital transfer to the geriatric unit to hospital discharge.  
The post-intervention group also showed a decrease in STOPP START criteria from hospital 
admission to transfer to the geriatric unit suggesting that the acute care provided on the medical and 
surgical wards was associated with a reduction in potentially inappropriate prescribing.  It is unclear 
why the pre-intervention group had no significant decrease in STOPP START criteria during the 
acute care phase as there were no known differences in the approach to prescribing over the study 
periods.  One explanation could be that the two groups had other, unidentified, differences which 
influenced the baseline number of STOPP START criteria which were met on admission to 
hospital.  Our observations of the decrease in STOPP START criteria in the geriatric unit is 
consistent with international results that support the collaboration of a pharmacist and geriatrician to 
improve prescribing in an inpatient geriatric unit84. 
 
The most frequent START criteria observed in both the pre- and post-intervention groups was the 
use of calcium and vitamin D supplement in patients with known osteoporosis.  Calcium and 
vitamin D supplementation in the treatment of osteoporosis are well accepted in literature and 
international guidelines107 108 and this study period was before concerns were raised regarding the 
safety of calcium supplementation109.  During the pre-intervention phase there was no significant 
change in patient proportions at the different timepoints.  In contrast, this amount was significantly 
different in the post intervention group, there were 28 patients on transfer to the geriatric unit with a 
diagnosis of osteoporosis with no calcium and vitamin D supplementation which then decreased to 
11 at discharge, a considerable improvement in prescribing.  
 
The small but significant decrease in inappropriate benzodiazepine use in the post-intervention 
group demonstrates potentially appropriate deprescribing in these patients.  Deprescribing, or the 
trial withdrawal of specific classes of medications that may be inappropriate for the individual 
patient is associated with a reduced incidence of ADEs105.  Previous data has highlighted multi-
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disciplinary medication review by a pharmacist and physician can reduce the rate of potentially 
inappropriate prescribing in an outpatient clinic setting by targeted deprescribing106.  The most 
prevalent STOPP criteria for both groups; proton pump inhibitor (PPI) use for peptic ulcer disease 
at full therapeutic dosage for > 8 weeks, did not change significantly in either group. There are 
multiple risks associated with chronic PPI use including an association with a higher fracture rate103 
and increased risk of developing dementia104.   These risks are particularly relevant to older patients 
and the high proportions seen in our results represent a potentially missed opportunity for 
appropriate deprescribing.   
 
An unexpected finding in this study was a significant increase in the median number of medications 
prescribed between hospital admission and hospital discharge.  Both the pre- and post-intervention 
groups increased the median number of medications per patient by one over this timeframe.  Indeed, 
such increases in ‘appropriate’ prescribing are likely to be advantageous for patients, but in many 
cases, the prescription of each additional medication above 5 medications per patient increases the 
risk of medication misadventure112.  Of course polypharmacy alone is not a clinically useful marker 
of the quality use of medicines22.  The medication type and dose, rather than the number of 
medications, would be more predictive of clinical effects including potential ADEs30.  In both 
groups the increased number of medications may be offset by a decrease in the number of STOPP 
START criteria and improved prescribing quality.  An example is the increased number of patients 
prescribed calcium and vitamin D supplements if they have osteoporosis in the post-intervention 
group.  In the post intervention group there appeared to be an increase in several medications, 
specifically the prescribing of calcium channel blockers (CCB) (Table 4) this could be due to an 
increase in patients requiring further control of their blood pressure and increased use of tricyclic 
antidepressants and opioids for pain (Table5).   
 
Small sample numbers may have limited the statistical power to detect changes in prescribing 
quality using the STOPP START criteria.  The generalizability of these results is also a study 
limitation, these results were achieved in a large, metropolitan tertiary hospital with a specialist 
geriatric team.  There were also staff changes to the pharmacist and medical staff during the study 
period.  The experience, communication skills and competencies of the individual pharmacists and 
prescribers were not investigated during this study however the effect of individual pharmacist or 
prescriber competencies compared with clinical interventions would be an interesting area of further 
research.  
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4.5 Conclusion 
In this study, the improved appropriateness of prescribing, as measured by reduced STOPP START 
criteria in the post-intervention group, are encouraging for pharmacist participation on physician-led 
ward rounds.  We also observed that the collaborative, multi-disciplinary model of care in the 
specialised geriatric unit also improved prescribing quality for both groups in comparison to the 
changes made to prescribing within the acute care wards.  In conclusion, pharmacist participation 
on ward rounds has potential to support appropriateness of prescribing in a specialised geriatric 
unit.   
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 Chapter 5: Thesis Discussion and Conclusion 
5.1 Introduction  
This Thesis describes the current patterns of potentially inappropriate prescribing in elderly patients 
who had a hospital admission, before and after the inclusion of a pharmacist on the physician-led 
ward round in a specialised geriatric unit.  The STOPP START tool was used to assess medication 
prescribing across a patient’s hospital admission, from admission, to transfer to the specialised 
geriatric or GEM unit and on hospital discharge.  The results of these cohort studies are suggestive 
of a model that supports improved prescribing quality for geriatric patients by combining a 
collaborative, multi-disciplinary GEM team with pharmacist participation on physician-led ward 
rounds.  This chapter reflects on the key findings of this thesis, limitations of this work and directions 
for future research before reaching the thesis conclusion. 
 
5.2 Summary of the Key Findings 
The aim of this Thesis was to assess the effect of pharmacist ward round participation on prescribing 
quality as assessed by the STOPP-START tool in hospitalised geriatric patients.  A pre- and post-
intervention, observational cohort study was used to assess the effect of the addition of the clinical 
pharmacist to the physician ward round.  The STOPP START criteria were applied at three time-
points (admission to hospital, transfer to the GEM unit, and on hospital discharge) to assess whether 
any changes in prescribing quality were present across the hospital admission for both the pre- and 
post-intervention group.  Analysis of the medication prescribing patterns in 196 patients (96 patients 
in the pre-intervention group and 100 patients in the post-intervention group) identified key trends of 
potentially inappropriate prescribing as described below. 
 
5.2.1 Description of Prescribing Patterns for Patients Through-out a Hospital Admission 
Chapter 3 demonstrated that prescribing quality improves after patient admission to a specialised 
geriatric unit as there was a decrease in STOPP START criteria between transfer to the geriatric unit 
and discharge for both this pre-intervention group.  The specialised geriatric unit at RBWH has a 
collaborative multi-disciplinary model including a pharmacist and geriatric physician.  Chapter 4 
further demonstrated that the post-intervention group also had a decrease in potentially inappropriate 
prescribing from GEM unit transfer to hospital discharge.  This is consistent with previous research 
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that has showed that a collaborative physician-pharmacist approach to prescribing and medication 
review in an inpatient geriatric unit led to improved medication appropriateness84.   
 
The pre-intervention group did not show a significant change in prescribing quality from hospital 
admission to transfer to the GEM unit.  The post-intervention group had a significant decrease in 
mean number of STOPP START criteria from hospital admission to transfer to the GEM unit, 
however this research did not focus on why this may have occurred.   
 
Our data was also compared with previously published Australian and international data, as detailed 
in chapter 3.   As most of the published data reported a proportion of patients that met at least one 
criteria this was also evaluated.  When the prescribing pattern was reviewed in this manner there was 
no significant change in prescribing from admission to discharge in the proportions for this group.  In 
the pre-intervention group on admission to hospital, 57% of patients met at least one STOPP criteria 
and 50% met at least one START criteria and these rates were similar on transfer to the specialised 
geriatric unit it was 58% and 49% respectively and at discharge was 54% for STOPP criteria and 42% 
for START criteria.  A similar study of Australian hospital inpatients identified 60% of patients had 
at least one STOPP criteria upon admission to hospital63. Irish studies have identified rates of STOPP 
criteria between 34-50% in hospital patients and 60% in nursing home patients62.  Studies across six 
European countries (Switzerland, Spain, Ireland, Czech Republic, Italy and Belguim) found an 
overall rate of 51.3% for STOPP criteria and 59.4% for START criteria for hospital patients56.  As 
this was the first study to follow prescribing across transitions of care using STOPP START, it is 
hard to make direct comparisons, however these rates appear similar.  The post-intervention group 
did show a trend of decreased proportion of patients meeting at least one STOPP criteria at each time-
point; from 64% at admission to 53% on transfer to the specialised geriatric unit to 42% at discharge.  
Similar proportions were seen for START criteria with 58% of patients meeting at least one START 
criteria on admission, 44% on transfer to the specialised geriatric unit and 35% at discharge   
 
A Swedish study found a mean number of STOPP START criteria of 1.85 on hospital admission90.  
In this Thesis, the mean number of criteria on discharge were 1.0 for the post-intervention group and 
2.2 for the pre-intervention group90.   These results are similar to the mean number of criteria found 
in this study; on hospital admission 1.78 for the pre-intervention group and 2.30 for the post-
intervention group and on discharge 1.5 for the pre-intervention group and 1.18 for the post-
intervention group. 
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5.2.2 Description of the Number of Medications Prescribed Throughout a Hospital Admission for 
Elderly Patients 
Interestingly, we observed a significant increase in the mean number of medications prescribed on 
admission (7.3 per patient in the pre-intervention group, 7.9 per patient in the post-intervention group) 
to that prescribed on discharge, (8.8 per patient in the pre-intervention group, 9.3 per patient in the 
post-intervention group) for the pre- and post-intervention groups, p<0.01. Whilst the number of 
medications prescribed seems high, polypharmacy alone should not be considered a clinically useful 
marker of the potentially inappropriate prescribing22.  The increased prescribing quality as indicated 
by a decrease in potentially inappropriate prescribing, as measured using STOPP START criteria, 
during the hospital admission would suggest that the slight increase in number of medications could 
indicate more appropriate prescribing.  
 
5.2.3 Evaluation of the Impact of Pharmacist Participation on Physician-led Ward Rounds on 
Prescribing Quality 
Prescribing patterns, namely the mean number of STOPP START criteria met at each time-point in 
each cohort, were compared between the pre and post intervention group.  It was evident that there 
were less criteria met on discharge for the post-intervention group compared to the pre-intervention 
group.  Whilst this decrease did not reach statistical significance it is likely to be clinically significant.  
A mean decrease of 0.32 criteria for the post-intervention group compared to the pre-intervention 
group could translate clinically, for every 3 patients there would be 1 less criteria for potentially 
inappropriate prescribing.  This is likely to be significant as each criteria represents a prescribing 
situation which has been identified as likely to cause an ADE in this patient population.  This is 
encourageing that pharmacist participation on the physician-led ward round may decrease the amount 
of potentially inappropriate prescribing.  Previous literature had suggested that pharmacist 
involvement on physician led ward rounds can decrease ADEs in intensive care units92 and general 
medical units93 95.  The decrease in potentially inappropriate prescribing described in Chapter 4, 
supports a model of care that includes the pharmacist on the physician-led ward round in a specialised 
geriatric unit.   
 
5.2.4 Comments on Individual Criteria 
The most prevalent STOPP criteria for both groups; PPI prescription for peptic ulcer disease at full 
therapeutic dosage for > 8 weeks is consistent with other study data that showed that PPI use within 
the wider patient group is very common103.  The Royal Australian College of General Practitioners 
have made the statement: “Don’t use PPIs long term in patients with uncomplicated disease without 
regular attempts at reducing dose or ceasing” as their leading statement as part of the Choosing Wisely 
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Australia initiative113.  There are significant risks associated with chronic PPI use including an 
association with a higher fracture rate103, increased risk of community acquired pneumonia, 
gastrointestinal infection, interstitial nephritis and nutritional deficiencies114 in addition to an 
increased risk of developing dementia104.  These are important reasons why all prescribers should 
carefully review the use and duration of PPI therapy.  The lack of significant change could be viewed 
as a missed opportunity during the hospital admission for both patient groups.   
 
The small decrease in inappropriate benzodiazepine use in both groups demonstrates appropriate 
deprescribing in this patient group.  The trial withdrawal of specific classes of medications that may 
be inappropriate for the individual patient, also known as deprescribing, can lead to an improvement 
in ADEs105.  There can also be decreased medication costs to the patient and healthcare system, 
improved medication adherence and improved patient satisfaction from taking fewer medications105.  
There is evidence that multi-disciplinary review by a pharmacist and physician can improve the rate 
of potentially inappropriate prescribing in an outpatient clinic setting by targeting deprescribing106.  
Of note, the Canadian Deprescribing Group are targeting both benzodiazepines and PPIs to improve 
prescribing in elderly patients115.  Primary Health Tasmania have also included benzodiazepines and 
PPIs in their deprescribing targets116.  
 
For both the pre- and post-intervention groups the most frequent START criteria was the use of 
calcium and vitamin D supplement in patients with known osteoporosis.  The pre-intervention group 
showed no significant change in patient proportions at the different time-points.  The post-
intervention group had a significant decrease from 28 patients on geriatric unit transfer to 11 at 
discharge, a significant change in prescribing.  Calcium and vitamin D supplementation in the 
treatment of osteoporosis are well accepted in literature and guidelines107 108 and this study period 
was before concerns were raised in the literature regarding the safety of calcium supplementation109.  
Such a significant change in prescribing is encourageing and there was anecdotal evidence in the 
medical notes that the assessment of vitamin D serum levels was prompted by the pharmacist on the 
ward rounds in a large number of patients. 
 
5.3 Recommendation for Future Research 
5.3.1 Expanding Pharmacists on Ward Rounds in Other Clinical Areas 
This thesis presents evidence that the inclusion of a pharmacist on ward rounds can lead to potentially 
increased prescribing quality and less ADEs for patients in a specialised geriatric unit.  This adds to 
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evidence that pharmacist inclusion on ward rounds can improve pharmacotherapy in intensive care 
units92 and general medical units93 95.  Future research work would be required to establish if this 
improved prescribing quality and potential decreased risk of ADEs can be translated to other clinical 
areas.  Also it would be of value to perform qualitative studies to describe why a pharmacist on a 
ward round confers these apparent benefits.  This is especially pertinent as participating on a ward 
round can be a time consuming and would represent a change in model of care for most clinical 
pharmacists.  Indeed, such benefits may not be realised in all other specialties or clinical areas that 
do not have the same focus on medications.  It would also be of value to further investigate the nature 
of the communication that occurs during the ward round that makes this setting conducive to making 
decisions around better prescribing.  An extension of this direction could be further qualitative work 
in evaluating patient preferences around the prescribing decision making, ensuring the patient is the 
centre of any decision regarding their health.   
 
5.3.2 Decision-Making Around Prescribing Decisions 
During the data collection periods it was noted that there were occasions where a pharmacist had 
suggested a change in prescribing that did not occur, but if it had it may have improved prescribing 
quality.  This suggestion was often communicated through the medication action plan (MAP) or in 
the patient’s medical notes.  The ward rounds occurred once or twice a week and these suggestions 
may not have been timed to allow their discussion on that ward round.  There was also anecdotal 
evidence during the data collection that indicated the junior medical doctors did not feel empowered 
to change a patient’s medications, as that decision may have been made by a more senior doctor.  
Time constraints meant that further qualitative work to investigate the nature of prescribing decision-
making was not investigated as part of this thesis but work in this area would provide further direction 
on how to target interventions to improve prescribing.  
 
With the advances of computer technology towards a paperless hospital with electronic prescribing, 
it will be of interest to assess the role of computerised medication management support.  There is 
work underway to have STOPP START integrated into a computerised decision support tool to guide 
more appropriate prescribing, and results of such interventions will be of interest61.  Common criteria 
identified by these results, and other similar studies, could be used to guide targeted interventions on 
high-profile criteria or medications. 
 
5.3.4 Pharmacist Prescribing 
A further interesting future direction would be exploring the impact of pharmacist prescribing on 
medication appropriateness.  In some Canadian provinces where pharmacists can prescribe the 
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evidence is promising.  A pharmacist prescribing model for hypertension resulted in better clinical 
outcomes, with the intervention group having a greater proportion of patients reach the blood pressure 
target and the pharmacist prescribing group showed a significant decrease in systolic and diastolic 
blood pressure117.  Of interest, the pharmacist prescribing group had more medication changes, 
pharmacists initiated more hypertension and cardiovascular medications, ceased more medications 
and had more dose changes than the control group117.  Similar clinical improvements have been 
achieved in Canada for pharmacist interventions in cholesterol lowering118 119 and pharmacist 
management of insulin initiation in type 2 diabetes patients120.  As pharmacist prescribing expands 
its scope of practice it will be interesting to evaluate if pharmacists can further impact the quality of 
prescribing in other areas.  Clinical improvements are a promising start to more appropriate 
prescribing and future work could also analyse how this model (pharmacist prescribing) compares to 
traditional medical, and other non-medical, prescribing in geriatric patients. 
 
5.3.5 Deprescribing 
The process of reviewing a patient’s medications; which spans therapy initiation, dose titration, 
changing or adding drugs, and switching or ceasing drug is part of the good prescribing continuum121 
but may have suffered from a lack of identity.  The term “deprescribing” has been proposed as the 
process of tapering or stopping drugs, aimed at minimizing polypharmacy and improving patient 
outcomes121.  A five stage process has been proposed by an Australian network and consists of: 
(1) ascertain all drugs the patient is currently taking and the reasons for each one;  
(2) consider overall risk of drug-induced harm in individual patients in determining the required 
intensity of deprescribing intervention; 
(3) assess each drug in regard to its current or future benefit potential compared with current or 
future harm or burden potential;  
(4) prioritize drugs for discontinuation that have the lowest benefit-harm ratio and lowest 
likelihood of adverse withdrawal reactions or disease rebound syndromes;  
(5) implement a discontinuation regimen and monitor patients closely for improvement in 
outcomes or onset of adverse effects121. 
When this process was applied to patients admitted to an acute medical ward in a large, Australian, 
tertiary hospital a significant decrease was achieved in the median number of medications with an 
overall decrease of 34.3%122.  Whilst the results suggest a positive patient outcome, there was no 
measure of medication appropriateness or clinical outcomes122. 
 
The outlined deprescribing process is consistent with decreasing potentially inappropriate prescribing 
and improving prescribing quality however the term has been slow to gain traction in the literature 
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and in practice.  This could be in part due to a lack of familiarity with the term123, however there have 
been more publications recently in international literature121 and Canada has a deprescribing 
network115.  Future research into “deprescribing” as the process is outlined above should give further 
insight into how the relationship between evidence based medicine and individual patients continues 
to evolve. 
5.4 Limitations  
Time and feasibility ensured that data was collected for a total of 196 patients.  The end analysis of 
the primary aim resulted in a non-statistically significant result.  Larger patient numbers may have 
increased the power of this study to demonstrate a significant result.   
 
This Thesis used a retrospective, observational comparison of two groups.  It is possible that data 
may have been missed, particularly as the data collection was passive and did not impact on 
prescribing at the time.  It would be of value to observe the prescribing patterns of the physician-led 
ward round “live” and explore the nature of the interactions between prescribers, pharmacists, nurses 
and the patient. 
 
The data collection and analysis of the individual patient’s medication and conditions with the STOPP 
START criteria was performed by the author and could be a potential source of bias.  The STOPP 
START tool was designed to be explicit and the criteria are written in a way that ensures ease of use.  
STOPP START has also been shown to have a large degree on inter-user reliability64.   
 
This was a novel topic to examine and there were limited examples in the literature of similar work.  
To answer the aims of this Thesis, the STOPP START tool was used to measure prescribing quality, 
not simply detect potentially inappropriate prescribing. The STOPP START tool was designed to be 
a set of criteria to detect potentially inappropriate prescribing.  As a tool, STOPP START may lack 
the sensitivity required to detect a change in prescribing quality. 
 
The generalisability of these results is also a limitation, as these studies were collected in a large, 
metropolitan tertiary hospital in Australia with a specialist geriatric team led by consultant 
geriatricians.  Clinical pharmacists in Australia are already involved in many aspects of medication 
management, such as medication review and reconciliation, and are often working collaboratively 
with prescribers.  Other healthcare settings may differ and as such results may differ if a similar model 
or intervention is used.   
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As this Thesis was conducted in a busy healthcare environment there could be other factors that 
changed during the study that could have affected the results.  This could include, but is not limited 
to, staffing changes, adaptation and more familiarity with models of care and unit management, 
prescriber changes such as prescribers becoming more competent later in the year with more 
experience and subtle differences in patient populations that could influence prescribing patterns. 
5.5 Conclusion 
Specialised geriatric unit admission improves prescribing quality, as measured by less STOPP 
START criteria on discharge compared to transfer to the geriatric unit for both our cohort groups.  
Within the geriatric unit patients received multi-disciplinary care with a collaborative approach 
including a geriatric physician and a pharmacist.  This model appears effective in improving 
prescribing quality.  The lesser amount of STOPP START criteria for the post-intervention group is 
evidence that pharmacist participation on physician ward rounds can improve prescribing quality.  
This Thesis supports pharmacist participation on ward rounds as a valuable addition to the 
pharmaceutical care provided by clinical pharmacists.  This Thesis provides encouraging evidence 
that a model of care that combines multi-disciplinary, expert geriatric care in an specialised inpatient 
unit with the pharmacist directly participating on the physician-led ward round leads to improved 
medication appropriateness. 
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Appendix C: Data Collection Tool – Impact of Pharmacist STOPP START 
Patient Identification __________________   
Age(years):  ______________ 
Sex:  Male  О    Female  О 
Data Collection Date: _________ 
Dates for: 
RBWH Admission__________     Admission to GEM unit______________      Discharge 
____________ 
Length of Stay (days) Acute:  ___________  GEM____________ 
Weight:________  Height:__________  LBW:_________ 
Cr:_____________                    CrCl:________ 
Presenting Complaint:____________________________________________ 
Medical 
History:_________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________ 
Allergies:________________________________________________________________________
_______ 
Admission Residence:   Home О    Independent Living  О   Carer’s Home О    Hostel О    Nursing 
Home О 
Number of Medications: 
Admission:______________  GEM Admission___________ Discharge____________________ 
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Admission: 
STOPP Medications Identified 
Criteria Medication Comment 
   
   
   
START Medications Identified 
Criteria  Medication Comment 
   
   
   
 
GEM Admission 
STOPP Medications Identified 
Criteria Medication Comment 
   
   
   
START Medications Identified 
Criteria  Medication Comment 
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Discharge 
STOPP Medications Identified 
Criteria Medication Comment 
   
   
   
START Medications Identified 
Criteria  Medication Comment 
   
   
   
 
Comments (if a medication is stopped or started describe who initiated the change) 
________________________________________________________________________________
________________________________________________________________________________
__________________ 
 
Discharge Destination:  
Residential Transition Care О   Community Transition Care О      Home О    Independent Living О    
Carer’s Home О    Independent Living О       Hostel О        Nursing Home О 
Medication Cost ($): 
Admission_____________  GEM Admission_________________  Discharge__________________ 
30 day readmission:  Yes  О       No  О 
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Appendix D: STOPP: Screening Tool of Older People’s potentially 
inappropriate prescriptions. 
 
The following drug prescriptions are potentially inappropriate in persons aged 65 years. 
 
A Cardiovascular system 
1 Digoxin at a long-term dose >125 mg day1  with impaired renal function*. 
2 Loop diuretic for dependent ankle oedema only, i.e.no clinical signs of heart failure. 
3 Loop diuretic as first-line monotherapy for hypertension. 
4 Thiazide diuretic with a history of gout. 
5 Noncardioselective b-blocker with chronic obstructive pulmonary disease (COPD). 
6 b-Blocker in combination with verapamil. 
7 Use of diltiazem or verapamil with New York Heart Association Class III or IV heart failure. 
8 Calcium channel blockers with chronic constipation. 
9 Use of aspirin and warfarin in combination without histamine H2 receptor antagonist (except 
cimetidine because of interaction with warfarin) or proton pump inhibitor (PPI). 
10 Dipyridamole as monotherapy for cardiovascular secondary prevention. 
11 Aspirin with a past history of peptic ulcer disease without histamine H2 receptor antagonist or 
PPI. 
12 Aspirin at dose >150 mg day-1. 
13 Aspirin with no history of coronary, cerebral or peripheral vascular symptoms or occlusive event. 
14 Aspirin to treat dizziness not clearly attributable to cerebrovascular disease. 
15Warfarin for first, uncomplicated deep venous thrombosis for >6 months’ duration. 
16Warfarin for first uncomplicated pulmonary embolus for >12 months’ duration. 
17 Aspirin, clopidogrel, dipyridamole or warfarin with concurrent bleeding disorder. 
*Serum creatinine >150 mmol l-1, or estimated glomerular filtration rate (GFR) <50 ml min-1. 
 
B Central nervous system and psychotropic drugs 
1 Tricyclic antidepressants (TCAs) with dementia. 
2 TCAs with glaucoma. 
3 TCAs with cardiac conductive abnormalities. 
4 TCAs with constipation. 
5 TCAs with an opiate or calcium channel blocker. 
6 TCAs with prostatism or prior history of urinary retention. 
75 
 
7 Long-term (i.e. >1 month), long-acting benzodiazepines, e.g. chlordiazepoxide, flurazepam, 
nitrazepam, 
chlorazepate and benzodiazepines with long-acting metabolites, e.g. diazepam. 
8 Long-term (i.e. >1 month) neuroleptics as long-term hypnotics. 
9 Long-term neuroleptics (>1 month) in those with parkinsonism. 
10 Phenothiazines in patients with epilepsy. 
11 Anticholinergics to treat extrapyramidal side-effects of neuroleptic medications. 
12 Selective serotonin re-uptake inhibitors (SSRIs) with a history of clinically significant 
hyponatraemia. 
13 Prolonged use (>1 week) of first-generation antihistamines, i.e.diphenydramine, 
chlorpheniramine, cyclizine, promethazine. 
 
C Gastrointestinal system 
1 Diphenoxylate, loperamide or codeine phosphate for treatment of diarrhoea of unknown cause. 
2 Diphenoxylate, loperamide or codeine phosphate for treatment of severe infective gastroenteritis, 
i.e. bloody diarrhoea, high fever or severe systemic toxicity. 
3 Prochlorperazine (Stemetil) or metoclopramide with parkinsonism. 
4 PPI for peptic ulcer disease at full therapeutic dosage for >8 weeks. 
5 Anticholinergic antispasmodic drugs with chronic constipation. 
D Respiratory system 
1 Theophylline as monotherapy for COPD. 
2 Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in moderate–
severe 
COPD. 
3 Nebulized ipratropium with glaucoma. 
 
E Musculoskeletal system 
1 Nonsteroidal anti-inflammatory drug (NSAID) with history of peptic ulcer disease or 
gastrointestinal bleeding, unless with concurrent histamine H2 receptor antagonist, PPI or 
misoprostol. 
2 NSAID with moderate–severe hypertension. 
3 NSAID with heart failure. 
4 Long-term use of NSAID (>3 months) for symptom relief of mild osteoarthritis. 
5Warfarin and NSAID together. 
6 NSAID with chronic renal failure*. 
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7 Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthritis or osteoarthritis. 
8 Long-term NSAID or colchicine for chronic treatment of gout where there is no contraindication to 
allopurinol. 
*Serum creatinine >150 mmol l-1, or estimated GFR 20–50 ml min-1. 
 
F Urogenital system 
1 Bladder antimuscarinic drugs with dementia. 
2 Antimuscarinic drugs with chronic glaucoma. 
3 Antimuscarinic drugs with chronic constipation. 
4 Antimuscarinic drugs with chronic prostatism. 
5 a-Blockers in men with frequent incontinence, i.e. one or more episodes of incontinence daily. 
6 a-Blockers with long-term urinary catheter in situ, i.e. >2 months. 
 
G Endocrine system 
1 Glibenclamide or chlorpropamide with Type 2 diabetes mellitus. 
2 b-Blockers in those with diabetes mellitus and frequent hypoglycaemic episodes, i.e._1 episode per 
month. 
3 Oestrogens with a history of breast cancer or venous thromboembolism. 
4 Oestrogens without progestogen in patients with intact uterus. 
 
H Drugs that adversely affect fallers 
1 Benzodiazepines. 
2 Neuroleptic drugs. 
3 First-generation antihistamines. 
4 Vasodilator drugs with persistent postural hypotension, i.e. recurrent >20 mmHg drop in systolic 
blood pressure. 
5 Long-term opiates in those with recurrent falls. 
 
I Analgesic drugs 
1 Use of long-term powerful opiates, e.g. morphine or fentanyl as first-line therapy for mild–moderate 
pain. 
2 Regular opiates for >2 weeks in those with chronic constipation without concurrent use of laxatives. 
3 Long-term opiates in those with dementia unless indicted for palliative care or management 
ofmoderate– 
severe chronic pain syndrome. 
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J Duplicate drug classes 
Any duplicate drug class prescription, e.g. two concurrent opiates, NSAIDs, SSRIs, loop diuretics, 
ACE inhibitors. 
 
 
START: Screening Tool to Alert doctors to Right, i.e. appropriate, indicated 
but often omitted treatments. 
 
These medications should be considered for people >65 years of age with the following conditions, 
where no contraindication to prescription exists. 
 
A Cardiovascular system 
1Warfarin in the presence of chronic atrial fibrillation (AF). 
2 Aspirin in the presence of chronic AF, where warfarin is contraindicated, but not aspirin. 
3 Aspirin or clopidogrel with a documented history of atherosclerotic coronary, cerebral or peripheral 
vascular 
disease in patients with sinus rhythm. 
4 Antihypertensive therapy where systolic blood pressure consistently >160 mmHg. 
5 Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease, where 
the patient’s functional status remains independent for activities of daily living and life expectancy 
is >5 
years. 
6 Angiotensin converting enzyme (ACE) inhibitor with chronic heart failure. 
7 ACE inhibitor following acute myocardial infarction. 
8 b-Blocker with chronic stable angina. 
 
B Respiratory system 
1.Regular inhaled b2 agonist or anticholinergic agent for mild to moderate asthma or chronic 
obstructive pulmonary disease (COPD). 
2 Regular inhaled corticosteroid for moderate–severe asthma or COPD, where predicted forced 
expiratory 
volume in 1 s <50%. 
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3 Home continuous oxygen with documented chronic type 1 respiratory failure (pO2 <8.0 kPa,pCO2 
<6.5 kPa) or type 2 respiratory failure (pO2 < 8.0 kPa, pCO2 > 6.5 kPa). 
 
C Central nervous system 
1 L-DOPA in idiopathic Parkinson’s disease with definite functional impairment and resultant 
disability. 
2 Antidepressant drug in the presence of moderate–severe depressive symptoms lasting at least 3 
months. 
 
D Gastrointestinal system 
1 Proton pump inhibitor with severe gastro-oesophageal acid reflux disease or peptic stricture 
requiring dilation. 
2 Fibre supplement for chronic, symptomatic diverticular disease with constipation. 
 
E Musculoskeletal system 
1 Disease-modifying antirheumatic drug with active moderate–severe rheumatoid disease lasting >12 
weeks. 
2 Bisphosphonates in patients taking maintenance corticosteroid therapy. 
3 Calcium and Vitamin D supplement in patients with known osteoporosis (previous fragility fracture, 
acquired 
dorsal kyphosis). 
 
F Endocrine system 
1Metformin with Type 2 diabetes metabolic syndrome (in the absence of renal impairment*). 
2 ACE inhibitor or angiotensin receptor blocker in diabetes with nephropathy, i.e. overt urinalysis 
proteinuria or 
microalbuminuria (>30 mg per 24 h) serum biochemicalrenal impairment*. 
3 Antiplatelet therapy in diabetes mellitus with co-existing major cardiovascular risk factors 
(hypertension, hypercholesterolaemia, smoking history). 
4 Statin therapy in diabetes mellitus if coexisting major cardiovascular risk factors present. 
*Serum creatinine >150 mmol l-1, or estimated GFR <50 ml min-1. 
 
 
